MXPA02001911A - Anticuerpos ctla-4 humanos y sus usos. - Google Patents

Anticuerpos ctla-4 humanos y sus usos.

Info

Publication number: MXPA02001911A
Authority: MX; Mexico
Prior art keywords: antibodies; human ctla; human; ctla; infections
Prior art date: 1999-08-24

Application number

MXPA02001911A

Other languages

English (en)

Inventor

Alan J Korman

Original Assignee

Medarex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-24

Filing date

2000-08-24

Publication date

2003-07-21

2000-08-24 Application filed by Medarex Inc filed Critical Medarex Inc

2003-07-21 Publication of MXPA02001911A publication Critical patent/MXPA02001911A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Environmental Sciences (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Oncology (AREA)
Animal Husbandry (AREA)
General Engineering & Computer Science (AREA)
Biodiversity & Conservation Biology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)

MXPA02001911A 1999-08-24 2000-08-24 Anticuerpos ctla-4 humanos y sus usos. MXPA02001911A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15045299P	1999-08-24	1999-08-24
PCT/US2000/023356 WO2001014424A2 (en)	1999-08-24	2000-08-24	Human ctla-4 antibodies and their uses

Publications (1)

Publication Number	Publication Date
MXPA02001911A true MXPA02001911A (es)	2003-07-21

Family

ID=22534598

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA02001911A MXPA02001911A (es)	1999-08-24	2000-08-24	Anticuerpos ctla-4 humanos y sus usos.

Country Status (21)

Country	Link
US (1)	US6984720B1 (es)
EP (4)	EP2829609A1 (es)
JP (4)	JP4093757B2 (es)
KR (3)	KR20020047132A (es)
CN (2)	CN1371416B (es)
AT (1)	ATE354655T1 (es)
AU (3)	AU784012B2 (es)
BE (1)	BE2012C001I2 (es)
CA (2)	CA2381770C (es)
CY (2)	CY1107628T1 (es)
DE (2)	DE60033530T2 (es)
DK (1)	DK1212422T3 (es)
ES (1)	ES2282133T3 (es)
FR (1)	FR12C0004I2 (es)
IL (3)	IL148079A0 (es)
LU (1)	LU91928I2 (es)
MX (1)	MXPA02001911A (es)
NZ (1)	NZ517202A (es)
PT (1)	PT1212422E (es)
WO (1)	WO2001014424A2 (es)
ZA (1)	ZA200201190B (es)

Families Citing this family (1074)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69938871D1 (de) *	1998-12-03	2008-07-17	Univ California	Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen
US7109003B2 (en)	1998-12-23	2006-09-19	Abgenix, Inc.	Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en)	1998-12-23	2004-01-27	Abgenix, Inc.	Human monoclonal antibodies to CTLA-4
CA2356215C (en) *	1998-12-23	2015-11-24	Pfizer Inc.	Human monoclonal antibodies to ctla-4
ATE354655T1 (de) *	1999-08-24	2007-03-15	Medarex Inc	Humane antikörper gegen ctla-4 und deren verwendungen
US7605238B2 (en) *	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
US7034121B2 (en) *	2000-01-27	2006-04-25	Genetics Institue, Llc	Antibodies against CTLA4
WO2001066754A1 (en)	2000-03-03	2001-09-13	Cambridge Antibody Technology Limited	Human antibodies against eotaxin and their use
US6946546B2 (en)	2000-03-06	2005-09-20	Cambridge Antibody Technology Limited	Human antibodies against eotaxin
ES2614260T3 (es)	2000-05-26	2017-05-30	Immunex Corporation	Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos
JP4986370B2 (ja)	2000-12-22	2012-07-25	マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ	Ｒｇｍおよびそのモジュレーターの用途
EP1478751A4 (en)	2001-03-30	2005-10-19	Avigenics Inc	LYSOZYM PROMOTER IN BIRDS
US7541512B2 (en)	2001-03-30	2009-06-02	Synageva Biopharma Corp.	Avians containing a lysozyme promoter transgene
IL149701A0 (en) *	2001-05-23	2002-11-10	Pfizer Prod Inc	Use of anti-ctla-4 antibodies
AR038568A1 (es) *	2002-02-20	2005-01-19	Hoffmann La Roche	Anticuerpos anti-a beta y su uso
AU2003234736B2 (en)	2002-04-12	2008-09-25	E. R. Squibb & Sons, L.L.C.	Methods of treatment using CTLA-4 antibodies
WO2003092624A2 (en) *	2002-05-02	2003-11-13	University Of Connecticut Health Center	Use of heat shock proteins to enhance efficacy of antibody therapeutics
ES2348230T3 (es)	2002-06-07	2010-12-01	Dyax Corp.	Prevención y reducción de la isquemia.
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
EP2206517B1 (en)	2002-07-03	2023-08-02	Ono Pharmaceutical Co., Ltd.	Immunopotentiating compositions comprising anti-PD-L1 antibodies
PT2386310T (pt)	2002-08-28	2019-02-05	Dyax Corp	Métodos para preservar órgãos e tecidos
US20080260744A1 (en) *	2002-09-09	2008-10-23	Omeros Corporation	G protein coupled receptors and uses thereof
WO2004040000A2 (en) *	2002-09-09	2004-05-13	Nura, Inc	G protein coupled receptors and uses thereof
WO2004029629A1 (en) *	2002-09-27	2004-04-08	Janssen Pharmaceutica N.V.	N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
EP1549678A4 (en) *	2002-09-30	2006-01-18	Pfizer Prod Inc	HYBRIDOMAS THAT PRODUCE HIGH CONCENTRATIONS OF ANTIBODIES TO THE HUMAN SEQUENCE
NZ568769A (en)	2002-10-17	2010-04-30	Genmab As	Human monoclonal antibodies against CD20
JP4739763B2 (ja) *	2002-12-16	2011-08-03	ゲンマブエー／エス	インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CN102040662A (zh)	2003-03-14	2011-05-04	惠氏有限责任公司	抗人il-21受体的抗体及其应用
ATE549359T1 (de)	2003-04-02	2012-03-15	Hoffmann La Roche	Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen
CN101318019B (zh)	2003-04-23	2012-08-29	梅达雷克斯公司	含1型干扰素拮抗剂的组合物及其在制备治疗炎症性肠病的药物中的用途
US7465446B2 (en) *	2003-05-30	2008-12-16	Medarex, Inc.	Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
CA2528549A1 (en) *	2003-06-06	2005-06-02	Medimmune, Inc.	Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer
US7579157B2 (en)	2003-07-10	2009-08-25	Hoffmann-La Roche Inc.	Antibody selection method against IGF-IR
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
US8101720B2 (en) *	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
EP1531162A1 (en) *	2003-11-14	2005-05-18	Heinz Vollmers	Adenocarcinoma specific antibody SAM-6, and uses thereof
US7642341B2 (en)	2003-12-18	2010-01-05	Merck Serono S.A.	Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en)	2003-11-19	2005-05-25	RMF Dictagene S.A.	Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
PT1691837E (pt)	2003-12-10	2012-08-27	Medarex Inc	Anticorpos ip-10 e suas utilizações
SI2418220T1 (sl)	2003-12-10	2017-10-30	E. R. Squibb & Sons, L.L.C.	Interferon alfa protitelesa in njihova uporaba
RS51908B (sr)	2004-02-06	2012-02-29	University of Massachusetts	Antitela protiv toksina clostridium difficile i njihove primene
WO2005092380A2 (en) *	2004-03-26	2005-10-06	Pfizer Products Inc	Uses of anti-ctla-4 antibodies
PL1737891T3 (pl)	2004-04-13	2013-08-30	Hoffmann La Roche	Przeciwciała przeciw selektynie p
CA2568661A1 (en)	2004-06-03	2006-01-05	Medarex, Inc.	Human monoclonal antibodies to fc gamma receptor i (cd64)
US7494779B2 (en)	2004-06-14	2009-02-24	Li-Te Chin	Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
US20050276758A1 (en) *	2004-06-15	2005-12-15	Marshall Deborah J	Method for screening agents against human prostate disease
DK1781705T3 (en)	2004-06-21	2015-01-12	Squibb & Sons Llc	Interferon-alpha receptor 1 antibodies and uses thereof
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006056464A2 (en)	2004-11-26	2006-06-01	Pieris Ag	Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1827470A2 (en) *	2004-12-09	2007-09-05	Neuro Therapeutics AB	Materials and methods related to dickkopfs (dkk) and neurogenesis
KR101262058B1 (ko) *	2005-02-08	2013-05-08	잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼	항체를 개선하기 위한 방법
JP2006249083A (ja)	2005-03-08	2006-09-21	Pharmacia & Upjohn Co Llc	抗ｍ−ｃｓｆ抗体組成物
AU2014240252B2 (en) *	2005-03-08	2016-10-06	Pfizer Products Inc	Anti-CTLA-4 Antibody Compositions
AU2012200203B2 (en) *	2005-03-08	2014-07-03	Pfizer Products Inc.	Anti-CTLA-4 Antibody Compositions
JP5225069B2 (ja)	2005-03-23	2013-07-03	ゲンマブエー／エス	多発性骨髄腫の治療のためのｃｄ３８に対する抗体
RU2007134867A (ru) *	2005-03-23	2009-04-27	Пфайзер Продактс Инк. (Us)	Терапия рака предстательной железы ctla4-антителами и гормональной терапией
US20060240006A1 (en) *	2005-04-20	2006-10-26	Chishih Chu	Novel antibody structures derived from human germline sequences
DE102005019845A1 (de) *	2005-04-28	2006-11-02	Li-Te Chin	Neue aus humanen Keimbahnsequenzen gewonnene Antikörperstrukturen
PL2161336T5 (pl)	2005-05-09	2017-10-31	Ono Pharmaceutical Co	Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
DK1907000T4 (da) *	2005-06-08	2020-03-30	The President And Fellows Of Harvard College	Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
CN104356236B (zh)	2005-07-01	2020-07-03	E.R.施贵宝&圣斯有限责任公司	抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007008463A2 (en) *	2005-07-07	2007-01-18	Coley Pharmaceutical Group, Inc.	Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
PL1915398T3 (pl) *	2005-07-18	2016-10-31		Ludzkie przeciwciała neutralizujące anty-B7RP1
CN100443503C (zh) *	2005-07-18	2008-12-17	四川大学华西医院	人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
NL1029605C2 (nl) *	2005-07-25	2007-01-26	Li-Te Chin	Nieuwe uit menselijke kiemlijnsequenties gewonnen antilichaamstructuren.
NZ595387A (en)	2005-08-11	2013-04-26	Arpi Matossian Rogers	Peptides for treatment and diagnosis of autoimmune disease
EA016186B1 (ru)	2005-09-26	2012-03-30	Медарекс, Инк.	Человеческие моноклональные антитела к cd70 и их применение
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2624562A1 (en) *	2005-09-30	2007-04-12	Abbott Gmbh & Co. Kg	Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
MY144906A (en)	2005-10-21	2011-11-30	Novartis Ag	Human antibodies against il13 and therapeutic uses
JP2009514977A (ja)	2005-11-08	2009-04-09	メダレックスインコーポレーティッド	免疫刺激性治療用抗体による治療に付随した腸炎に対するＴＮＦ−α遮断剤処置法
JP5475994B2 (ja)	2005-11-30	2014-04-16	アッヴィ・インコーポレイテッド	抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
KR101439828B1 (ko)	2005-11-30	2014-09-17	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
CN101325971A (zh)	2005-12-07	2008-12-17	米德列斯公司	Ctla-4抗体剂量递增方案
PL1960434T3 (pl)	2005-12-08	2012-12-31	Squibb & Sons Llc	Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1
ES2396569T3 (es)	2006-01-17	2013-02-22	Medarex, Inc.	Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo y xilosilo
WO2007123737A2 (en)	2006-03-30	2007-11-01	University Of California	Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) *	2006-03-31	2011-04-05	Biosante Pharmaceuticals, Inc.	Cancer immunotherapy compositions and methods of use
AU2007235496B2 (en)	2006-03-31	2013-11-21	E. R. Squibb & Sons, L.L.C.	Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2010226B1 (en) *	2006-04-07	2014-01-15	The Research Foundation of State University of New York	Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
JP2009533028A (ja)	2006-04-07	2009-09-17	ザガバメントオブザユナイテッドステイツオブアメリカアズリプレゼンティッドバイザセクレタリーデパートメントオブヘルスアンドヒューマンサービシーズ	新生物疾患の治療のための抗体組成物および方法
US9044461B2 (en)	2006-04-07	2015-06-02	The Research Foundation Of State University Of New York	Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7846724B2 (en)	2006-04-11	2010-12-07	Hoffmann-La Roche Inc.	Method for selecting CHO cell for production of glycosylated antibodies
EP2046834B9 (en)	2006-08-11	2013-04-10	Ono Pharmaceutical Co., Ltd.	Monoclonal antibodies against stromal derived factor-1 (sdf-1)
CA2662350A1 (en)	2006-09-05	2008-03-13	Medarex, Inc.	Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
PT2081595T (pt)	2006-09-26	2019-07-16	Genmab As	Anti-cd38 mais corticosteroides mais um quimioterápico não corticosteroide para tratar tumores
EP2068928A2 (en)	2006-09-28	2009-06-17	Merck Serono SA	Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
SI2486941T1 (sl)	2006-10-02	2017-08-31	E. R. Squibb & Sons, L.L.C.	Humana protitelesa, ki vežejo CXCR4 in njihova uporaba
DK2068922T3 (da)	2006-10-19	2012-10-08	Csl Ltd	Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
US8618248B2 (en)	2006-10-31	2013-12-31	President And Fellows Of Harvard College	Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
AU2007334264A1 (en)	2006-11-15	2008-06-26	Medarex, Inc.	Human monoclonal antibodies to BTLA and methods of use
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2097097B1 (en)	2006-12-01	2018-05-30	E. R. Squibb & Sons, L.L.C.	Antibodies, in particular human antibodies, that bind cd22 and uses thereof
CL2007003622A1 (es)	2006-12-13	2009-08-07	Medarex Inc	Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
NZ578354A (en)	2006-12-14	2012-01-12	Medarex Inc	Antibody-partner molecule conjugates that bind cd70 and uses thereof
WO2009077483A1 (en)	2007-12-14	2009-06-25	Novo Nordisk A/S	Antibodies against human nkg2d and uses thereof
DK2716301T3 (en)	2007-02-16	2017-07-31	Merrimack Pharmaceuticals Inc	ANTIBODIES AGAINST ERBB3 AND APPLICATIONS THEREOF
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
WO2008109075A2 (en) *	2007-03-05	2008-09-12	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to ctla-4 antagonists
MX2009010282A (es)	2007-03-29	2009-10-12	Genmab As	Anticuerpos biespecificos y metodos para su produccion.
FI20075278A0 (fi)	2007-04-20	2007-04-20	Biotie Therapies Corp	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
EP2164873B2 (en)	2007-05-31	2018-09-12	Genmab A/S	Stable igg4 antibodies
EP3255144A1 (en)	2007-08-10	2017-12-13	E. R. Squibb & Sons, L.L.C.	Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
CA3128656A1 (en)	2007-08-22	2009-02-26	The Regents Of The University Of California	Activatable binding polypeptides and methods of identification and use thereof
US8865875B2 (en)	2007-08-22	2014-10-21	Medarex, L.L.C.	Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
WO2009032845A2 (en)	2007-09-04	2009-03-12	Compugen, Ltd.	Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2033971A1 (de) *	2007-09-06	2009-03-11	Abbott GmbH & Co. KG	Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
AR068767A1 (es)	2007-10-12	2009-12-02	Novartis Ag	Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
ES2663077T3 (es)	2007-11-02	2018-04-11	Novartis Ag	Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
JP2011509299A (ja)	2008-01-08	2011-03-24	ブリストル−マイヤーズスクイブカンパニー	増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
US8263073B2 (en)	2008-02-04	2012-09-11	Medarex, Inc.	Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
EP2650017A3 (en)	2008-02-05	2014-01-22	Bristol-Myers Squibb Company	Alpha 5 - beta 1 antibodies and their uses
US8962803B2 (en) *	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
AU2009255357A1 (en) *	2008-05-29	2009-12-10	Bristol-Myers Squibb Company	Methods for predicting patient response to modulation of the co-stimulatory pathway
WO2010014784A2 (en)	2008-08-01	2010-02-04	Bristol-Myers Squibb Company	Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
ES2643411T3 (es)	2008-08-05	2017-11-22	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a la proteína del complemento C5
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8475790B2 (en)	2008-10-06	2013-07-02	Bristol-Myers Squibb Company	Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
EP2370593B1 (en) *	2008-11-28	2016-03-30	Emory University	Methods for determining the efficacy of pd-1 antagonists
AU2009324092A1 (en)	2008-12-03	2011-06-23	Genmab A/S	Antibody variants having modifications in the constant region
US20110311450A1 (en)	2008-12-08	2011-12-22	Zurit Levine	Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
UA109633C2 (uk)	2008-12-09	2015-09-25		Антитіло людини проти тканинного фактора
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
CN106995495A (zh)	2009-01-12	2017-08-01	希托马克斯医疗有限责任公司	修饰抗体组合物及其制备和使用方法
PL2387627T3 (pl) *	2009-01-15	2016-10-31		Profilowanie odporności adaptacyjnej i wytwarzanie przeciwciał monoklonalnych
CN102481341B (zh) *	2009-02-23	2017-05-17	希托马克斯医疗有限公司	蛋白原及其使用方法
GB0903325D0 (en)	2009-02-26	2009-04-08	Univ Aberdeen	Antibody molecules
LT2403878T (lt)	2009-03-05	2017-10-10	E. R. Squibb & Sons, L.L.C.	Pilnai žmogaus specifiniai antikūnai, skirti cadm1
WO2010117325A1 (en)	2009-04-08	2010-10-14	Olle Hernell	New methods for treatment of inflammatory diseases
WO2010124113A1 (en)	2009-04-23	2010-10-28	Infinity Pharmaceuticals, Inc.	Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
JP2012524524A (ja)	2009-04-27	2012-10-18	ノバルティスアーゲー	ＩＬ−１２レセプターβ１サブユニットに特異的な治療用抗体の組成物および使用方法
CA2758290C (en)	2009-04-27	2018-04-10	Novartis Ag	Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
US20120101262A1 (en)	2009-06-25	2012-04-26	Bristol-Myers Squibb Company	Protein purification by caprylic acid (octanoic acid) precipitation
SMT201700293T1 (it)	2009-07-20	2017-07-18	Bristol Myers Squibb Co	Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative
US8394922B2 (en)	2009-08-03	2013-03-12	Medarex, Inc.	Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011021146A1 (en)	2009-08-20	2011-02-24	Pfizer Inc.	Osteopontin antibodies
EP2480561B1 (en)	2009-09-23	2016-07-13	E. R. Squibb & Sons, L.L.C.	Cation exchange chromatography
CN102740887B (zh)	2009-09-30	2015-04-15	斯隆凯特林防癌纪念中心	用于治疗癌症的组合免疫疗法
US8435516B2 (en)	2009-10-12	2013-05-07	Pfizer Inc.	Cancer treatment
MX2012004682A (es)	2009-10-26	2012-09-07	Hoffmann La Roche	Metodo para la produccion de una inmunoglobulina glicosilada.
NO2501822T3 (es)	2009-11-17	2018-01-13
EP2507265B1 (en)	2009-12-01	2016-05-11	Compugen Ltd.	Antibody specific for heparanase splice variant T5 and its use.
ES2562832T3 (es)	2009-12-08	2016-03-08	Abbvie Deutschland Gmbh & Co Kg	Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
RS62853B1 (sr) *	2010-01-06	2022-02-28	Takeda Pharmaceuticals Co	Proteini koji vezuju kalikrein plazme
CA3254586A1 (en)	2010-03-10	2025-11-29	Genmab A/S	Monoclonal anti bodi es against c-met
AU2011232435B2 (en)	2010-03-23	2016-01-28	Intrexon Corporation	Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
US10745467B2 (en)	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en)	2012-06-22	2015-08-20	Randolph J. Noelle	VISTA Antagonist and Methods of Use
EP3153521B1 (en)	2010-03-26	2019-09-04	Trustees of Dartmouth College	Vista regulatory t cell mediator protein, vista binding agents and use thereof
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
MX2012012441A (es)	2010-05-04	2013-02-26	Merrimack Pharmaceuticals Inc	Anticuerpos contra el receptor del factor de crecimiento epidermico (egfr) y usos de los mismos.
WO2011140151A1 (en)	2010-05-04	2011-11-10	Dyax Corp.	Antibodies against epidermal growth factor receptor (egfr)
EP2566892B1 (en)	2010-05-06	2017-12-20	Novartis AG	Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
CA2798390A1 (en)	2010-05-06	2011-11-10	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
US20130064831A1 (en)	2010-05-17	2013-03-14	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens and combinations thereof
CA2800785C (en)	2010-05-27	2019-09-24	Genmab A/S	Monoclonal antibodies against her2
CA2800769C (en)	2010-05-27	2021-11-02	Genmab A/S	Monoclonal antibodies against her2 epitope
SI2580243T1 (sl)	2010-06-09	2020-02-28	Genmab A/S	Protitelesa proti humanemu CD38
CA2802782C (en)	2010-06-15	2018-03-13	Genmab A/S	Human antibody drug conjugates against tissue factor
CA2803391C (en)	2010-06-22	2021-11-09	Neogenix Oncology, Inc.	Npc1 antibodies that bind a muc5ac epitope
EP2600901B1 (en)	2010-08-06	2019-03-27	ModernaTX, Inc.	A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
PL2606070T3 (pl)	2010-08-20	2017-06-30	Novartis Ag	Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
US8999335B2 (en)	2010-09-17	2015-04-07	Compugen Ltd.	Compositions and methods for treatment of drug resistant multiple myeloma
CA3182320A1 (en)	2010-09-23	2012-03-29	Precision Biologics, Inc.	Colon and pancreas cancer peptidomimetics
CN104531812A (zh)	2010-10-01	2015-04-22	现代治疗公司	设计核酸及其使用方法
EP2625203A1 (en)	2010-10-05	2013-08-14	Novartis AG	Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
WO2012069466A1 (en)	2010-11-24	2012-05-31	Novartis Ag	Multispecific molecules
WO2012072806A1 (en)	2010-12-02	2012-06-07	Pieris Ag	Muteins of human lipocalin 2 with affinity for ctla-4
KR101904232B1 (ko)	2010-12-14	2018-10-05	내셔널 유니버시티 오브 싱가포르	뎅기 바이러스 세로타입 1 e 프로틴에 특이적인 인간 단일클론 항체 및 그들의 용도
CA2860170C (en)	2010-12-22	2022-06-14	The Board Of Trustees Of The Leland Stanford Junior University	Superagonists and antagonists of interleukin-2
CN103635489B (zh)	2011-01-06	2016-04-13	戴埃克斯有限公司	血浆前激肽释放酶结合蛋白
WO2012118693A1 (en)	2011-02-28	2012-09-07	Northshore University Healthsystem	Methods of diagnosing clostridium difficile infection
GB201103955D0 (en)	2011-03-09	2011-04-20	Antitope Ltd	Antibodies
US8710200B2 (en)	2011-03-31	2014-04-29	Moderna Therapeutics, Inc.	Engineered nucleic acids encoding a modified erythropoietin and their expression
WO2012136552A1 (en)	2011-04-08	2012-10-11	H. Lundbeck A/S	ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9150644B2 (en)	2011-04-12	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
SG10201603034TA (en)	2011-04-15	2016-05-30	Compugen Ltd	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CA2832389A1 (en)	2011-04-20	2012-10-26	Genmab A/S	Bispecific antibodies against her2 and cd3
EP2699260B1 (en)	2011-04-20	2024-11-20	Genmab A/S	Bispecifc antibodies against her2
WO2012143523A1 (en)	2011-04-20	2012-10-26	Genmab A/S	Bispecifc antibodies against her2
WO2012149540A1 (en)	2011-04-28	2012-11-01	The Broad Institute Inc	Inhibitors of histone deacetylase
CA2837184C (en)	2011-05-25	2021-09-21	Innate Pharma, S.A.	Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
US8852599B2 (en)	2011-05-26	2014-10-07	Bristol-Myers Squibb Company	Immunoconjugates, compositions for making them, and methods of making and use
US8691231B2 (en)	2011-06-03	2014-04-08	Merrimack Pharmaceuticals, Inc.	Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
RU2641256C2 (ru)	2011-06-30	2018-01-16	Чугаи Сейяку Кабусики Кайся	Гетеродимеризованный полипептид
EP2726503B1 (en)	2011-06-30	2019-09-04	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
PL2726099T3 (pl)	2011-07-01	2018-12-31	Novartis Ag	Sposób leczenia zaburzeń metabolicznych
UA117901C2 (uk)	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013010955A1 (en)	2011-07-15	2013-01-24	Morphosys Ag	Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9120858B2 (en)	2011-07-22	2015-09-01	The Research Foundation Of State University Of New York	Antibodies to the B12-transcobalamin receptor
HUE042327T2 (hu)	2011-08-30	2019-06-28	Astex Pharmaceuticals Inc	Decitabin-származék készítmények
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
BR112014007852B1 (pt)	2011-10-03	2021-11-03	Moderna Therapeutics, Inc	Polinucleotídeo isolado modificado e composição farmacêutica
DK2579042T3 (da)	2011-10-04	2014-07-21	Affiris Ag	Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
EP3653222A1 (en)	2011-10-14	2020-05-20	Novartis AG	Antibodies and methods for wnt pathway-related diseases
SG11201402783YA (en)	2011-12-05	2014-06-27	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
BR112014013568A2 (pt)	2011-12-05	2017-06-13	Novartis Ag	anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
CN107459576A (zh)	2011-12-14	2017-12-12	艾伯维德国有限责任两合公司	用于诊断和治疗铁相关病症的组合物和方法
MX356933B (es)	2011-12-14	2018-06-20	Abbvie Deutschland	Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
PL2791160T3 (pl)	2011-12-16	2022-06-20	Modernatx, Inc.	Kompozycje zmodyfikowanego mrna
SG10201703249PA (en)	2011-12-21	2017-05-30	Novartis Ag	Compositions and methods for antibodies targeting factor p
MY194587A (en)	2012-01-27	2022-12-05	Abbvie Inc	Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
BR112014018481A2 (pt)	2012-02-01	2017-07-04	Compugen Ltd	anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
DK2814829T3 (en)	2012-02-13	2017-03-20	Bristol Myers Squibb Co	RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES
ES2662128T3 (es)	2012-03-05	2018-04-05	Adaptive Biotechnologies Corporation	Determinación de cadenas de receptor inmunitario emparejadas a partir de la frecuencia de subunidades coincidentes
US20150110779A1 (en)	2012-03-15	2015-04-23	Bristol-Myers Squibb Company	Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
US20150079100A1 (en)	2012-03-23	2015-03-19	Bristol-Myers Squibb Company	Methods of treatments using ctla-4 antibodies
US10501512B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
HK1206779A1 (en)	2012-04-02	2016-01-15	Modernatx, Inc.	Modified polynucleotides for the production of nuclear proteins
KR102125658B1 (ko)	2012-05-04	2020-06-22	화이자 인코포레이티드	전립선 관련된 항원 및 백신 기재 면역치료 요법
MX354329B (es)	2012-05-08	2018-02-27	Adaptive Biotechnologies Corp	Composiciones y metodos para medir y calibrar el error de amplificacion en reacciones de pcr multiple.
US20150118244A1 (en)	2012-05-10	2015-04-30	Bristol-Myers Squibb Company	Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
SG10201700698WA (en)	2012-05-15	2017-02-27	Bristol Myers Squibb Co	Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN104619722B (zh)	2012-06-22	2022-10-04	达特茅斯大学理事会	新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
US9890215B2 (en)	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
UY34887A (es)	2012-07-02	2013-12-31	Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware	Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
BR112015000167B1 (pt)	2012-07-06	2021-11-23	Genmab B.V.	Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
EP3632462A1 (en)	2012-07-06	2020-04-08	Genmab B.V.	Dimeric protein with triple mutations
JP6337255B2 (ja)	2012-07-27	2018-06-06	ザブロードインスティテュート, インコーポレーテッドThe Broad Institute, Inc.	ヒストンデアセチラーゼの阻害剤
US9382329B2 (en) *	2012-08-14	2016-07-05	Ibc Pharmaceuticals, Inc.	Disease therapy by inducing immune response to Trop-2 expressing cells
WO2014036412A2 (en)	2012-08-30	2014-03-06	Amgen Inc.	A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
JOP20200308A1 (ar)	2012-09-07	2017-06-16	Novartis Ag	جزيئات إرتباط il-18
EP2892558B1 (en)	2012-09-07	2019-04-10	The Trustees Of Dartmouth College	Vista modulators for diagnosis and treatment of cancer
WO2015160439A2 (en)	2014-04-17	2015-10-22	Adaptive Biotechnologies Corporation	Quantification of adaptive immune cell genomes in a complex mixture of cells
WO2014066834A1 (en)	2012-10-26	2014-05-01	The University Of Chicago	Synergistic combination of immunologic inhibitors for the treatment of cancer
MX2015005831A (es)	2012-11-08	2015-09-24	Eleven Biotherapeutics Inc	Antagonistas de il-6 y usos de los mismos.
DK2922554T3 (en)	2012-11-26	2022-05-23	Modernatx Inc	Terminalt modificeret rna
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
CN104968364A (zh)	2012-12-03	2015-10-07	百时美施贵宝公司	强化免疫调变性Fc融合蛋白的抗癌活性
AU2013355414B2 (en)	2012-12-05	2017-02-02	Novartis Ag	Compositions and methods for antibodies targeting EPO
KR20150095684A (ko)	2012-12-18	2015-08-21	노파르티스 아게	히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
ES2667333T3 (es)	2012-12-28	2018-05-10	Precision Biologics, Inc.	Anticuerpos monoclonales humanizados y métodos de uso para el diagnóstico y el tratamiento del cáncer de colon y páncreas
EA201500741A1 (ru)	2013-01-10	2016-01-29	Генмаб Б.В.	ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
MA38322B1 (fr)	2013-02-08	2018-09-28	Novartis Ag	Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
SI2956173T1 (sl)	2013-02-14	2017-06-30	Bristol-Myers Squibb Company	Spojine tubulizina, postopki pridobivanja in uporaba
CN110448566A (zh)	2013-03-01	2019-11-15	阿斯泰克斯制药公司	药物组合
PH12022550138A1 (en)	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en)	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
EP3611189A1 (en)	2013-03-14	2020-02-19	Novartis AG	Antibodies against notch 3
WO2014153150A1 (en) *	2013-03-14	2014-09-25	Lee Delphine J	Methods of predicting anti ctla-4 response and recurrence of cancer
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US9469686B2 (en)	2013-03-15	2016-10-18	Abbott Laboratories	Anti-GP73 monoclonal antibodies and methods of obtaining the same
CN106211758B (zh)	2013-04-09	2021-03-23	北京强新生物科技有限公司	2-乙酰基萘并[2,3-b]呋喃-4,9-二酮用于治疗癌症的用途
KR101472903B1 (ko)	2013-05-16	2014-12-16	(주)케어젠	T 세포 활성 억제 펩타이드 및 이의 용도
WO2014186877A1 (en)	2013-05-24	2014-11-27	Uger Marni Diane	FasR ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE
WO2014197885A2 (en)	2013-06-07	2014-12-11	Duke University	Inhibitors of complement factor h
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9708657B2 (en)	2013-07-01	2017-07-18	Adaptive Biotechnologies Corp.	Method for generating clonotype profiles using sequence tags
EP3030262B1 (en)	2013-08-08	2019-10-09	Cytune Pharma	Combined pharmaceutical composition
HUE057598T2 (hu)	2013-08-08	2022-05-28	Cytune Pharma	IL-15 és IL-15R-alfa sushi domén alapú modulokinek
SG11201601047SA (en)	2013-08-14	2016-03-30	Univ Rice William M	Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
AU2014307589A1 (en)	2013-08-14	2016-02-11	Novartis Ag	Methods of treating sporadic inclusion body myositis
PT3508502T (pt)	2013-09-20	2023-06-22	Bristol Myers Squibb Co	Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
CN105722860A (zh)	2013-09-24	2016-06-29	梅迪塞纳医疗股份有限公司	白介素-2融合蛋白及其应用
WO2015048312A1 (en)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
CN105636986B (zh)	2013-10-18	2020-05-12	瑞泽恩制药公司	包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
HUE043042T2 (hu)	2013-11-01	2019-07-29	Pfizer	Vektorok prosztatához kapcsolódó antigének expressziójára
JP2016540042A (ja)	2013-11-05	2016-12-22	コグネートバイオサービシズ，インコーポレイテッド	がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
WO2015069703A1 (en)	2013-11-06	2015-05-14	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens and combinations thereof
SI3712174T1 (sl)	2013-12-24	2022-06-30	Janssen Pharmaceutica Nv	Protitelesa in delci proti VISTA
US11014987B2 (en)	2013-12-24	2021-05-25	Janssen Pharmaceutics Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3094650A2 (en)	2014-01-13	2016-11-23	Pieris Pharmaceuticals GmbH	Multi-specific polypeptide useful for localized tumor immunomodulation
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
EP3572430A3 (en)	2014-03-05	2020-02-12	Bristol-Myers Squibb Company	Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
LT3116909T (lt)	2014-03-14	2020-02-10	Novartis Ag	Antikūno molekulės prieš lag-3 ir jų panaudojimas
US10066265B2 (en)	2014-04-01	2018-09-04	Adaptive Biotechnologies Corp.	Determining antigen-specific t-cells
CN104974253A (zh) *	2014-04-01	2015-10-14	上海中信国健药业股份有限公司	抗ctla-4/pd-1双特异性抗体、其制备方法及应用
US11390921B2 (en)	2014-04-01	2022-07-19	Adaptive Biotechnologies Corporation	Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
SI3560954T1 (sl)	2014-04-03	2021-11-30	Igm Biosciences, Inc.	Spremenjena J-veriga
EP3134102B1 (en)	2014-04-24	2019-07-03	The Board of Trustees of The Leland Stanford Junior University	Superagonists, partial agonists and antagonists of interleukin-2
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
CN106459954A (zh)	2014-05-13	2017-02-22	中外制药株式会社	用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
RU2695332C2 (ru)	2014-05-15	2019-07-23	Бристол-Маерс Сквибб Компани	Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
SMT202100116T1 (it)	2014-05-28	2021-05-07	Agenus Inc	Anticorpi anti-gitr e metodi di utilizzo degli stessi
PT3151921T (pt)	2014-06-06	2019-11-21	Bristol Myers Squibb Co	Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
JP6997619B2 (ja)	2014-06-11	2022-01-17	キャシー・エイ・グリーン	液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
EP3160991A2 (en)	2014-06-25	2017-05-03	Novartis AG	Compositions and methods for long acting proteins
US20170291939A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Antibodies specific for il-17a fused to hyaluronan binding peptide tags
US10132818B2 (en)	2014-07-08	2018-11-20	New York University	Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
CN106999577B (zh)	2014-07-16	2021-12-21	特兰斯吉恩股份有限公司	溶瘤病毒和免疫检查点调节因子组合
PT3169341T (pt)	2014-07-16	2019-09-09	Transgene Sa	Vírus oncolítico para a expressão de moduladores de pontos de controlo imunitário
EP3174902B1 (en)	2014-08-01	2019-04-17	Institut National de la Sante et de la Recherche Medicale (INSERM)	An anti-cd45rc antibody for use as drug
CN105296433B (zh)	2014-08-01	2018-02-09	中山康方生物医药有限公司	一种ctla4抗体、其药物组合物及其用途
US9988443B2 (en)	2014-08-07	2018-06-05	Novartis Ag	Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
DK3177642T3 (da)	2014-08-07	2022-02-21	Novartis Ag	Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
NZ729395A (en)	2014-08-07	2018-04-27	Hyogo College Medicine	Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
JP6796058B2 (ja) *	2014-08-08	2020-12-02	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	インビトロおよびインビボにおける標的の光制御除去
EP3180018B1 (en)	2014-08-12	2019-07-24	Massachusetts Institute Of Technology	Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US20170224777A1 (en)	2014-08-12	2017-08-10	Massachusetts Institute Of Technology	Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
PL3186281T3 (pl)	2014-08-28	2019-10-31	Halozyme Inc	Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
CA2960824A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies of alk inhibitors
AU2015318018B2 (en)	2014-09-16	2017-05-11	Synermore Biologics (Suzhou) Co. Ltd.	Anti-EGFR antibody and uses of same
EP4029508A1 (en)	2014-10-10	2022-07-20	Idera Pharmaceuticals, Inc.	Treatment of cancer using tlr9 agonists and checkpoint inhibitors
EA201700181A1 (ru)	2014-10-14	2017-09-29	Галозим, Инк.	Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
WO2016059220A1 (en)	2014-10-16	2016-04-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Tcr-activating agents for use in the treatment of t-all
ES2784343T3 (es)	2014-10-29	2020-09-24	Adaptive Biotechnologies Corp	Detección simultánea altamente multiplexada de ácidos nucleicos que codifican heterodímeros de receptores inmunes adaptativos emparejados de muchas muestras
WO2016073401A1 (en)	2014-11-03	2016-05-12	Bristol-Myers Squibb Company	Use of caprylic acid precipitation for protein purification
WO2016073894A1 (en)	2014-11-07	2016-05-12	Eleven Biotherapeutics, Inc.	Therapeutic agents with increased ocular retention
PH12017500809B1 (en)	2014-11-07	2023-09-20	F Hoffmann La Roche Ltd	Improved il-6 antibodies
US10077287B2 (en)	2014-11-10	2018-09-18	Bristol-Myers Squibb Company	Tubulysin analogs and methods of making and use
US10246701B2 (en)	2014-11-14	2019-04-02	Adaptive Biotechnologies Corp.	Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
DK3221346T3 (da)	2014-11-21	2020-10-12	Bristol Myers Squibb Co	Antistoffer omfattende modificerede konstante områder af tungkæden
DK3221363T3 (da)	2014-11-21	2020-08-10	Bristol Myers Squibb Co	Antistoffer mod cd73 og anvendelser deraf
TN2017000223A1 (en)	2014-11-26	2018-10-19	Xencor Inc	Heterodimeric antibodies that bind cd3 and tumor antigens
MX2017007097A (es)	2014-12-04	2017-09-05	Bristol Myers Squibb Co	Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
AU2015357463B2 (en)	2014-12-05	2021-10-07	Immunext, Inc.	Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
TWI595006B (zh)	2014-12-09	2017-08-11	禮納特神經系統科學公司	抗ｐｄ－１抗體類和使用彼等之方法
KR20230107375A (ko)	2014-12-18	2023-07-14	암젠 인크	안정한 동결된 단순 포진 바이러스 제제
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
MA40662B1 (fr)	2014-12-23	2020-12-31	Bristol Myers Squibb Co	Anticorps contre tigit
CN104479019B (zh) *	2014-12-26	2020-07-21	上海复宏汉霖生物技术股份有限公司	一种抗ctla-4人源抗体
EP3240801B1 (en)	2014-12-31	2021-01-20	Checkmate Pharmaceuticals, Inc.	Combination tumor immunotherapy
JP6676058B2 (ja)	2015-01-14	2020-04-08	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
MA41414A (fr)	2015-01-28	2017-12-05	Centre Nat Rech Scient	Protéines de liaison agonistes d' icos
EP3250588A1 (en)	2015-01-29	2017-12-06	Board of Trustees of Michigan State University	Cryptic polypeptides and uses thereof
US20180028626A1 (en)	2015-02-13	2018-02-01	Transgene Sa	Immunotherapeutic vaccine and antibody combination therapy
CA2976446A1 (en)	2015-02-13	2016-08-18	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind ctla4
AU2016222788B2 (en)	2015-02-24	2022-03-31	Adaptive Biotechnologies Corp.	Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
MX395730B (es)	2015-03-13	2025-03-25	Bristol Myers Squibb Co	Uso de lavados alcalinos durante la cromatografia para remover impurezas.
US20180133327A1 (en)	2015-03-16	2018-05-17	Amal Therapeutics Sa	Cell Penetrating Peptides and Complexes Comprising the Same
US10196445B1 (en)	2015-03-17	2019-02-05	Bristol-Myers Squibb Company	Ipilimumab variant with enhanced ADCC
WO2016153983A1 (en)	2015-03-20	2016-09-29	Bristol-Myers Squibb Company	Use of dextran for protein purification
US20180105554A1 (en)	2015-03-20	2018-04-19	Bristol-Myers Squibb Company	Use of dextran sulfate to enhance protein a affinity chromatography
EP3735986A1 (en)	2015-03-23	2020-11-11	Jounce Therapeutics, Inc.	Antibodies to icos
US10376535B2 (en)	2015-03-26	2019-08-13	University Of Rochester	Therapy for malignant disease
EP3277294B1 (en)	2015-04-01	2024-05-15	Adaptive Biotechnologies Corp.	Method of identifying human compatible t cell receptors specific for an antigenic target
US10842848B2 (en)	2015-04-07	2020-11-24	Cytlimic Inc.	Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
US11215616B2 (en)	2015-04-10	2022-01-04	National Institutes Of Health (Nih), (Dhhs), U.S. Government	Methods of determining patient populations amenable to immunomodulatory treatment of cancer
DK3283107T3 (da)	2015-04-17	2020-08-31	Bristol Myers Squibb Co	Sammensætninger omfattende en kombination af ipilimumab og nivolumab
CN107534262B (zh)	2015-04-20	2019-10-15	三菱电机株式会社	激光器装置及极端远紫外光生成装置
EP3288980B1 (en)	2015-04-28	2021-03-10	Bristol-Myers Squibb Company	Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
EP3988571A1 (en)	2015-04-28	2022-04-27	Bristol-Myers Squibb Company	Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
EP4545082A3 (en)	2015-05-06	2025-07-02	SNIPR Technologies Limited	Altering microbial populations & modifying microbiota
WO2016183183A1 (en)	2015-05-11	2016-11-17	The Johns Hopkins University	Autoimmune antibodies for use in inhibiting cancer cell growth
BR112017024899A2 (pt)	2015-05-21	2018-11-13	Harpoon Therapeutics, Inc.	proteínas de ligação trispecíficas e métodos de uso.
EP3297674B1 (en)	2015-05-22	2023-01-04	Translational Drug Development Llc	Benzamide and active compound compositions and methods of use
US20180155429A1 (en)	2015-05-28	2018-06-07	Bristol-Myers Squibb Company	Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016196389A1 (en)	2015-05-29	2016-12-08	Bristol-Myers Squibb Company	Treatment of renal cell carcinoma
DK3303396T5 (da)	2015-05-29	2024-10-07	Bristol Myers Squibb Co	Antistoffer mod ox40 og anvendelser deraf
DK3303394T3 (da)	2015-05-29	2020-07-06	Agenus Inc	Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
CN107847481A (zh)	2015-06-03	2018-03-27	波士顿生物医药有限公司	包含癌症干性抑制剂的组合物和用于治疗癌症的免疫治疗剂
CA2982237A1 (en)	2015-06-05	2016-12-08	Novartis Ag	Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
WO2016207717A1 (en)	2015-06-24	2016-12-29	Janssen Pharmaceutica Nv	Anti-vista antibodies and fragments
KR20180021833A (ko)	2015-06-29	2018-03-05	더 락커펠러 유니버시티	증진된 효능제 활성을 갖는 cd40에 대한 항체
CA2990478A1 (en)	2015-06-29	2017-01-05	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
WO2017004532A1 (en)	2015-07-02	2017-01-05	Celgene Corporation	Combination therapy for treatment of hematological cancers and solid tumors
HK1254645A1 (zh)	2015-07-02	2019-07-26	Otsuka Pharmaceutical Co., Ltd.	冻乾药物组合物
JO3711B1 (ar)	2015-07-13	2021-01-31	H Lundbeck As	أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512215D0 (en)	2015-07-13	2015-08-19	Lundbeck & Co As H	Agents,uses and methods
GB201512203D0 (en)	2015-07-13	2015-08-19	Lundbeck & Co As H	Agents,uses and methods
FI3858859T3 (fi)	2015-07-14	2025-12-04	Bristol Myers Squibb Co	Menetelmä syövän hoitamiseksi käyttäen immunivasteen vapauttajaa; vasta-ainetta, joka sitoutuu ohjelmoidun solukuoleman 1 reseptoriin (pd-1) tai ohjelmoidun solukuoleman ligandi 1:een (pd-l1)
NZ739503A (en)	2015-07-16	2023-06-30	Bioxcel Therapeutics Inc	A novel approach for treatment of cancer using immunomodulation
AU2016291817A1 (en)	2015-07-16	2018-02-22	Biolinerx Ltd.	Compositions and methods for treating cancer
KR20180029079A (ko)	2015-07-31	2018-03-19	유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨.	암에 대한 면역 체크포인트 억제제와의 조합 요법에서의 조혈 줄기 세포
WO2017021893A1 (en)	2015-08-03	2017-02-09	Novartis Ag	Methods of treating fgf21-associated disorders
EP3331917A1 (en)	2015-08-04	2018-06-13	GlaxoSmithKline Intellectual Property Development Limited	Combination treatments and uses and methods thereof
WO2017025871A1 (en)	2015-08-07	2017-02-16	Glaxosmithkline Intellectual Property Development Limited	Combination therapy comprising anti ctla-4 antibodies
BR112018002585A2 (pt) *	2015-08-11	2018-10-16	Novartis Ag	5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amina para uso no tratamento de câncer
FI3334761T3 (fi)	2015-08-13	2023-08-14	Univ New York	Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
EP3341732B1 (en)	2015-08-27	2023-07-12	INSERM - Institut National de la Santé et de la Recherche Médicale	Methods for predicting the survival time of patients suffering from a lung cancer
WO2017040790A1 (en)	2015-09-01	2017-03-09	Agenus Inc.	Anti-pd-1 antibodies and methods of use thereof
ES2905554T3 (es)	2015-09-03	2022-04-11	Ono Pharmaceutical Co	Agente para aumentar la inmunidad frente al cáncer utilizando antagonista de Alergina-1
MY186352A (en)	2015-09-09	2021-07-15	Novartis Ag	Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
MX2018003038A (es)	2015-09-09	2018-04-11	Novartis Ag	Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
EP3347380B1 (en)	2015-09-11	2024-09-25	Nascent Biotech, Inc.	Enhanced delivery of drugs to the brain
RU2638457C2 (ru)	2015-09-28	2017-12-13	Общество С Ограниченной Ответственностью "Онкомакс"	Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
WO2017055325A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of nk cells in a tissue sample
WO2017055319A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of b cells in a tissue sample
WO2017055321A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055327A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055320A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055324A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055326A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055322A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of neutrophils in a tissue sample
AU2016329197B2 (en)	2015-09-30	2021-01-21	Igm Biosciences, Inc.	Binding molecules with modified J-chain
JP7058213B2 (ja) *	2015-09-30	2022-04-21	アイジーエムバイオサイエンシズインコーポレイテッド	改変ｊ鎖を有する結合分子
WO2017060397A1 (en)	2015-10-09	2017-04-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from melanoma metastases
ES2994611T3 (en)	2015-10-19	2025-01-27	Cg Oncology Inc	Methods of treating solid or lymphatic tumors by combination therapy
KR20180066236A (ko)	2015-10-22	2018-06-18	조운스 테라퓨틱스, 인크.	Icos 발현을 계측하기 위한 유전자 특질
SI3370733T1 (sl)	2015-11-02	2021-11-30	Board Of Regents The University Of Texas System	Postopek za aktivacijo CD40 in blokada imunske nadzorne točke
CN108350077A (zh)	2015-11-03	2018-07-31	糖模拟物有限公司	产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法
JP2018532810A (ja)	2015-11-07	2018-11-08	マルチビアインコーポレイテッド	がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物
US11072657B2 (en)	2015-11-18	2021-07-27	Bristol-Myers Squibb Company	Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
WO2017086367A1 (ja)	2015-11-18	2017-05-26	中外製薬株式会社	免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
US11649293B2 (en)	2015-11-18	2023-05-16	Chugai Seiyaku Kabushiki Kaisha	Method for enhancing humoral immune response
CN108738324B (zh)	2015-11-19	2022-06-21	百时美施贵宝公司	抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
CN107406504B (zh) *	2015-11-19	2021-04-30	蔡则玲	Ctla-4抗体及其用途
DK3383920T3 (da)	2015-11-30	2024-04-02	Univ California	Levering af tumorspecifik nyttelast og immunaktivering ved hjælp af et humant antistof rettet mod et meget specifikt tumorcelleoverfladeantigen
JP6849694B2 (ja)	2015-11-30	2021-03-24	ブリストル−マイヤーズスクウィブカンパニー	抗ヒトｉｐ−１０抗体およびそれらの使用
EP3383907B1 (en)	2015-12-01	2022-02-23	GlaxoSmithKline Intellectual Property Development Limited	Combination treatments and uses and methods thereof
TW202134282A (zh)	2015-12-02	2021-09-16	美商艾吉納斯公司	抗體和使用彼之方法
ES2863225T3 (es)	2015-12-03	2021-10-11	Glaxosmithkline Ip Dev Ltd	Dinucleótidos cíclicos purinos como moduladores del sting
KR20180085800A (ko)	2015-12-07	2018-07-27	젠코어 인코포레이티드	Cd3 및 psma에 결합하는 이종이합체성 항체
WO2017098421A1 (en)	2015-12-08	2017-06-15	Glaxosmithkline Intellectual Property Development Limited	Benzothiadiazine compounds
CN108602893A (zh)	2015-12-11	2018-09-28	戴埃克斯有限公司	血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
CR20180318A (es) *	2015-12-14	2018-09-19	Macrogenics Inc	Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
AU2016370813A1 (en)	2015-12-18	2018-06-28	Novartis Ag	Antibodies targeting CD32b and methods of use thereof
EA201891482A1 (ru)	2015-12-21	2018-12-28	Бристол-Маерс Сквибб Компани	Модифицированные антитела для сайт-специфической конъюгации
SI3394093T1 (sl)	2015-12-23	2022-05-31	Modernatx, Inc.	Metode uporabe liganda OX40, ki kodira polinukleotid
DK3399978T3 (da)	2016-01-08	2020-11-16	Celgene Corp	Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf
SG11201805777QA (en)	2016-01-08	2018-08-30	Celgene Corp	Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US10189808B2 (en)	2016-01-08	2019-01-29	Celgene Corporation	Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
US20190241658A1 (en)	2016-01-10	2019-08-08	Modernatx, Inc.	Therapeutic mRNAs encoding anti CTLA-4 antibodies
MX2018008797A (es)	2016-01-19	2018-11-29	Pfizer	Vacunas contra el cancer.
ES2847155T3 (es)	2016-01-21	2021-08-02	Novartis Ag	Moléculas multiespecíficas que fijan como objetivo CLL-1
US10918737B2 (en)	2016-01-28	2021-02-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of cancer
US10822415B2 (en)	2016-01-28	2020-11-03	Inserm (Institut National De La Santéet De La Recherche Médicale)	Methods for enhancing the potency of the immune checkpoint inhibitors
CN109069626A (zh)	2016-02-12	2018-12-21	詹森药业有限公司	抗-vista(b7h5)抗体
JP2019510078A (ja)	2016-02-23	2019-04-11	セセンバイオ，インコーポレイテッド	Ｉｌ−６アンタゴニスト製剤およびその使用
CA3013333A1 (en)	2016-02-26	2017-08-31	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antibodies having specificity for btla and uses thereof
US10894835B2 (en)	2016-03-04	2021-01-19	The Rockefeller University	Antibodies to CD40 with enhanced agonist activity
IL295230A (en)	2016-03-04	2022-10-01	Bristol Myers Squibb Co	Combination therapy with anti-cd73 antibodies
WO2017153952A1 (en)	2016-03-10	2017-09-14	Glaxosmithkline Intellectual Property Development Limited	5-sulfamoyl-2-hydroxybenzamide derivatives
EP3426271B1 (en)	2016-03-10	2025-08-27	CG Oncology, Inc.	Methods of treating solid tumors by combination therapy
WO2017160599A1 (en)	2016-03-14	2017-09-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of cd300b antagonists to treat sepsis and septic shock
EP3429693B1 (en)	2016-03-15	2023-08-23	Mersana Therapeutics, Inc.	Napi2b-targeted antibody-drug conjugates and methods of use thereof
AU2017234192B2 (en)	2016-03-16	2024-04-04	Amal Therapeutics Sa	Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
MA44483A (fr)	2016-03-24	2019-01-30	Millennium Pharm Inc	Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
TW201735949A (zh)	2016-03-24	2017-10-16	千禧製藥公司	治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US11542332B2 (en)	2016-03-26	2023-01-03	Bioatla, Inc.	Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109195990A (zh)	2016-03-30	2019-01-11	Musc研究发展基金会	通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
WO2017176925A1 (en)	2016-04-05	2017-10-12	Bristol-Myers Squibb Company	Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
WO2017175156A1 (en)	2016-04-07	2017-10-12	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides useful as protein modulators
CR20200045A (es)	2016-04-07	2020-03-11	Glaxosmithkline Ip Dev Ltd	AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
CN109311989A (zh)	2016-04-14	2019-02-05	创新微技术公司	在癌症疗法的治疗决定中的pd-l1表达的应用方法
EP3442579A4 (en)	2016-04-15	2019-12-18	Immunext Inc.	ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF
SG11201808821WA (en)	2016-04-18	2018-11-29	Celldex Therapeutics Inc	Agonistic antibodies that bind human cd40 and uses thereof
WO2017189976A1 (en)	2016-04-29	2017-11-02	Board Of Regents, The University Of Texas System	Targeted measure of transcriptional activity related to hormone receptors
WO2017192874A1 (en)	2016-05-04	2017-11-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Albumin-binding immunomodulatory compositions and methods of use thereof
BR112018072211A2 (pt)	2016-05-09	2019-02-12	Bristol-Myers Squibb Company	anticorpos anti tl1a e utilizações dos mesmos
CN109069665A (zh)	2016-05-10	2018-12-21	百时美施贵宝公司	具有增强的稳定性的微管溶素类似物的抗体-药物缀合物
SG10201603721TA (en)	2016-05-10	2017-12-28	Agency Science Tech & Res	Anti-CTLA-4 Antibodies
EP4137509A1 (en)	2016-05-18	2023-02-22	ModernaTX, Inc.	Combinations of mrnas encoding immune modulating polypeptides and uses thereof
SG11201809381XA (en)	2016-05-18	2018-12-28	Modernatx Inc	Polynucleotides encoding interleukin-12 (il12) and uses thereof
MA45037A (fr)	2016-05-18	2019-03-27	Modernatx Inc	Polythérapie à base d'arnm pour le traitement du cancer
WO2017201432A2 (en)	2016-05-19	2017-11-23	Jounaidi Youssef	Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
CN107400166A (zh)	2016-05-19	2017-11-28	苏州康宁杰瑞生物科技有限公司	针对ctla4的单域抗体及其衍生蛋白
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
JP7101621B2 (ja)	2016-05-20	2022-07-15	ハープーンセラピューティクス，インク．	単一ドメイン血清アルブミン結合タンパク質
CA3025019A1 (en)	2016-05-20	2017-11-23	Biohaven Pharmaceutical Holding Company Ltd.	Use of glutamate modulating agents with immunotherapies to treat cancer
IL305882B2 (en)	2016-05-25	2025-11-01	Inst Nat Sante Rech Med	Methods for producing a population of inactivated pluripotent cells
CA3026054A1 (en)	2016-05-30	2017-12-07	Geovax Inc.	Compositions and methods for generating an immune response to hepatitis b virus
WO2017210335A1 (en)	2016-06-01	2017-12-07	Bristol-Myers Squibb Company	Imaging methods using 18f-radiolabeled biologics
RS64388B1 (sr)	2016-06-02	2023-08-31	Bristol Myers Squibb Co	Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma
CN109475634A (zh)	2016-06-03	2019-03-15	百时美施贵宝公司	用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
KR102515509B1 (ko)	2016-06-03	2023-03-28	브리스톨-마이어스 스큅 컴퍼니	결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
GB201609811D0 (en)	2016-06-05	2016-07-20	Snipr Technologies Ltd	Methods, cells, systems, arrays, RNA and kits
CN109563034A (zh)	2016-06-08	2019-04-02	葛兰素史密斯克莱知识产权发展有限公司	化学化合物
BR112018075598A2 (pt)	2016-06-08	2019-03-26	Glaxosmithkline Intellectual Property Development Limited	compostos químicos
EP3468581A1 (en)	2016-06-13	2019-04-17	Torque Therapeutics, Inc.	Methods and compositions for promoting immune cell function
MA45255A (fr)	2016-06-14	2019-04-17	Xencor Inc	Anticorps inhibiteurs de points de contrôle bispécifiques
KR102492057B1 (ko)	2016-06-15	2023-01-26	노파르티스 아게	골 형태형성 단백질 6(ｂｍｐ6)의 억제제를 사용한 질병의 치료 방법
SG11201810509PA (en)	2016-06-20	2018-12-28	Kymab Ltd	Anti-pd-l1 antibodies
CN109640999A (zh)	2016-06-24	2019-04-16	无限药品股份有限公司	组合疗法
CN109983121A (zh)	2016-06-30	2019-07-05	昂克诺斯公司	治疗性多肽的假型化溶瘤病毒递送
JP7029415B2 (ja)	2016-07-12	2022-03-03	ハー・ルンドベック・アクチエゼルスカベット	過リン酸化タウに特異的な抗体およびその使用方法
WO2018011166A2 (en)	2016-07-12	2018-01-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of myeloid dendritic cells in a tissue sample
CA3030841A1 (en)	2016-07-14	2018-01-18	Fred Hutchinson Cancer Research Center	Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
BR112019000431A2 (pt)	2016-07-14	2019-07-09	Bristol-Myers Squibb Company	anticorpos contra tim3 e usos dos mesmos
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
KR20190028540A (ko)	2016-07-20	2019-03-18	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	Perk 억제제로서의 이소퀴놀린 유도체
US20190185567A1 (en) *	2016-08-01	2019-06-20	Ignyta, Inc.	Combinations for the treatment of cancer
NL2017270B1 (en) *	2016-08-02	2018-02-09	Aduro Biotech Holdings Europe B V	New anti-hCTLA-4 antibodies
WO2018025221A1 (en)	2016-08-04	2018-02-08	Glaxosmithkline Intellectual Property Development Limited	Anti-icos and anti-pd-1 antibody combination therapy
JP2019528312A (ja)	2016-08-07	2019-10-10	ノバルティスアーゲー	ｍＲＮＡ媒介性の免疫化方法
RU2764548C2 (ru)	2016-08-09	2022-01-18	Кимаб Лимитед	Анти-icos антитела
WO2018029336A1 (en)	2016-08-12	2018-02-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
KR20190039978A (ko)	2016-08-12	2019-04-16	브리스톨-마이어스 스큅 컴퍼니	단백질 정제 방법
CN110087680B (zh)	2016-08-19	2024-03-19	百济神州有限公司	使用包含btk抑制剂的组合产品治疗癌症
CN109641911B (zh)	2016-08-19	2023-02-21	百时美施贵宝公司	seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法
WO2018035710A1 (en) *	2016-08-23	2018-03-01	Akeso Biopharma, Inc.	Anti-ctla4 antibodies
WO2018044970A1 (en)	2016-08-31	2018-03-08	University Of Rochester	Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
WO2018046738A1 (en)	2016-09-12	2018-03-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from cancer
WO2018046736A1 (en)	2016-09-12	2018-03-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from cancer
EP4667012A2 (en)	2016-09-19	2025-12-24	OncoC4, Inc.	Cd80 and cd86 binding protein compositions and uses thereof
US10428325B1 (en)	2016-09-21	2019-10-01	Adaptive Biotechnologies Corporation	Identification of antigen-specific B cell receptors
KR102879364B1 (ko)	2016-09-21	2025-11-04	아말 테라퓨틱스 에스에이	암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
EP3515453A1 (en)	2016-09-22	2019-07-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
EA201990578A1 (ru)	2016-09-23	2019-10-31		Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
MX2019003447A (es)	2016-09-27	2019-08-29	Univ Texas	Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.
JP2019535015A (ja)	2016-10-03	2019-12-05	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	患者サンプルにおけるｇｆａｐ状況を評価する改善された方法
JP6976322B2 (ja) *	2016-10-10	2021-12-08	クラウンバイオサイエンス，インコーポレイテッド（タイツァン）	新規抗ｃｔｌａ４抗体
TWI773694B (zh)	2016-10-11	2022-08-11	美商艾吉納斯公司	抗ｌａｇ－３抗體及其使用方法
CN109982711A (zh)	2016-10-11	2019-07-05	Cytlimic公司	药物
WO2018068201A1 (en) *	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
SG11201903283UA (en)	2016-10-12	2019-05-30	Univ Texas	Methods and compositions for tusc2 immunotherapy
US10398783B2 (en)	2016-10-20	2019-09-03	Bristol-Myers Squibb Company	Antiproliferative compounds and conjugates made therefrom
KR20240019398A (ko)	2016-10-28	2024-02-14	브리스톨-마이어스 스큅 컴퍼니	항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11117968B2 (en) *	2016-11-03	2021-09-14	Bristol-Myers Squibb Company	Activatable anti-CTLA-4 antibodies and uses thereof
WO2018085698A1 (en)	2016-11-04	2018-05-11	Aximmune, Inc.	Beta-alethine, immune modulators, and uses thereof
CN110312523B (zh) *	2016-11-08	2024-04-26	齐鲁皮吉特湾生物治疗有限公司	抗pd1和抗ctla4抗体
CA3043356A1 (en)	2016-11-09	2018-05-17	Musc Foundation For Research Development	Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
CA3041340A1 (en)	2016-11-09	2018-05-17	Agenus Inc.	Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US12049511B2 (en)	2016-11-10	2024-07-30	Fortis Therapeutics, Inc.	Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
WO2018087391A1 (en)	2016-11-14	2018-05-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
WO2018087720A1 (en)	2016-11-14	2018-05-17	Novartis Ag	Compositions, methods, and therapeutic uses related to fusogenic protein minion
JP7217229B2 (ja)	2016-11-15	2023-02-02	ハー・ルンドベック・アクチエゼルスカベット	シヌクレイノパチーの治療のための薬剤、使用および方法
US11446302B2 (en)	2016-11-17	2022-09-20	Board Of Regents, The University Of Texas System	Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
WO2018098352A2 (en)	2016-11-22	2018-05-31	Jun Oishi	Targeting kras induced immune checkpoint expression
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
JP7080234B2 (ja)	2016-11-23	2022-06-03	トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー	ベンズアミドおよび活性化合物組成物および使用方法
CN106432499A (zh) *	2016-11-24	2017-02-22	上海美迪西生物医药股份有限公司	Ctla‑4抗体fab在昆虫表达系统中的制备方法
WO2018099539A1 (en)	2016-11-29	2018-06-07	Horst Lindhofer	Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
WO2018102427A1 (en)	2016-11-29	2018-06-07	Boston Biomedical, Inc.	Naphthofuran derivatives, preparation, and methods of use thereof
JP2020500878A (ja)	2016-12-01	2020-01-16	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	併用療法
KR20190090823A (ko)	2016-12-01	2019-08-02	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	조합 요법
AU2017373944B2 (en)	2016-12-07	2022-02-03	Agenus Inc.	Anti-CTLA-4 antibodies and methods of use thereof
FI3552126T3 (fi)	2016-12-09	2025-07-08	Regeneron Pharma	Järjestelmiä ja menetelmiä T-solureseptoreiden sekvensoimiseksi ja niiden käyttöjä
CN110381997A (zh)	2016-12-12	2019-10-25	茂体外尔公司	用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
WO2018110515A1 (ja) *	2016-12-12	2018-06-21	第一三共株式会社	抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
WO2018112266A1 (en)	2016-12-14	2018-06-21	The Board Of Trustees Of The Leland Stanford Junior University	Il-13 superkine: immune cell targeting constructs and methods of use thereof
CN110072888B (zh)	2016-12-16	2023-07-18	H.隆德贝克有限公司	药剂、用途和方法
WO2018112360A1 (en)	2016-12-16	2018-06-21	Evelo Biosciences, Inc.	Combination therapies for treating cancer
US10364286B2 (en)	2016-12-22	2019-07-30	H. Lundbeck A/S	Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN118047864A (zh)	2016-12-23	2024-05-17	百时美施贵宝公司	用于改进生物分析和生物加工特性的治疗性免疫球蛋白g4的设计
WO2018115458A1 (en)	2016-12-23	2018-06-28	Virttu Biologics Limited	Treatment of cancer
WO2018122249A1 (en)	2016-12-28	2018-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018122245A1 (en)	2016-12-28	2018-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
MA47205A (fr)	2017-01-04	2019-11-13	H Lundbeck As	Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires
WO2018129451A2 (en)	2017-01-09	2018-07-12	Merrimack Pharmaceuticals, Inc.	Anti-fgfr antibodies and methods of use
EP3568150A4 (en)	2017-01-10	2020-12-02	Xcella Biosciences, Inc.	POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
US10350266B2 (en)	2017-01-10	2019-07-16	Nodus Therapeutics, Inc.	Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3573979A1 (en)	2017-01-27	2019-12-04	Celgene Corporation	3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
WO2018146148A1 (en)	2017-02-07	2018-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	A method for predicting the response to checkpoint blockade cancer immunotherapy
WO2018146128A1 (en)	2017-02-07	2018-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
WO2018148381A1 (en)	2017-02-07	2018-08-16	Nantcell, Inc.	Maximizing t-cell memory and compositions and methods therefor
ES3035810T3 (en)	2017-02-08	2025-09-09	Novartis Ag	Fgf21 mimetic antibodies and uses thereof
WO2018151821A1 (en)	2017-02-17	2018-08-23	Bristol-Myers Squibb Company	Antibodies to alpha-synuclein and uses thereof
TWI674261B (zh)	2017-02-17	2019-10-11	美商英能腫瘤免疫股份有限公司	Nlrp3 調節劑
BR112019017583A2 (pt)	2017-02-24	2020-04-07	Board Of Regents, The University Of Texas System	ensaio para detecção de câncer pancreático em estágio inicial
CA3052767A1 (en)	2017-02-27	2018-08-30	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as kinase inhibitors
TW201834697A (zh)	2017-02-28	2018-10-01	美商梅爾莎納醫療公司	Her2標靶抗體－藥物結合物之組合療法
SG11201907867TA (en) *	2017-02-28	2019-09-27	Bristol Myers Squibb Co	Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
EP3366703B1 (en)	2017-02-28	2019-04-03	Ralf Kleef	Immune checkpoint therapy with hyperthermia
WO2018167778A1 (en)	2017-03-12	2018-09-20	Yeda Research And Development Co. Ltd.	Methods of diagnosing and prognosing cancer
WO2018167780A1 (en)	2017-03-12	2018-09-20	Yeda Research And Development Co. Ltd.	Methods of prognosing and treating cancer
JP2020510050A (ja)	2017-03-15	2020-04-02	アムジエン・インコーポレーテツド	がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用
CN106916226B (zh) *	2017-03-17	2020-01-14	信达生物制药(苏州)有限公司	以ctla-4为靶点的免疫调节药物治疗结核病的应用
CA3261113A1 (en)	2017-03-23	2025-10-27	Abbott Laboratories	Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
LT3600415T (lt)	2017-03-24	2025-12-29	Novartis Ag	Antikūnas prieš ii tipo aktivino receptorių, skirtas naudoti širdies nepakankamumo gydymui
KR20230148855A (ko)	2017-03-30	2023-10-25	더 존스 홉킨스 유니버시티	생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템
CA3058175A1 (en)	2017-03-31	2018-10-04	Bristol-Myers Squibb Company	Methods of treating tumor
WO2018187227A1 (en)	2017-04-03	2018-10-11	Concologie, Inc.	Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
AU2018251987B2 (en)	2017-04-14	2024-11-28	Cg Oncology, Inc.	Methods of treating bladder cancer
WO2018191531A1 (en)	2017-04-15	2018-10-18	Abbott Laboratories	Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
WO2018195552A1 (en)	2017-04-21	2018-10-25	Sillajen, Inc.	Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
CN110621341A (zh)	2017-04-26	2019-12-27	百时美施贵宝公司	使二硫键还原最小化的抗体生产方法
TW201900193A (zh)	2017-04-28	2019-01-01	美商默沙東藥廠	用於癌症治療之生物標記物
EP3635407B1 (en)	2017-04-28	2025-09-10	Abbott Laboratories	Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10865238B1 (en)	2017-05-05	2020-12-15	Duke University	Complement factor H antibodies
CA3063359A1 (en)	2017-05-12	2018-11-15	Harpoon Therapeutics, Inc.	Mesothelin binding proteins
WO2018213424A1 (en)	2017-05-17	2018-11-22	Boston Biomedical, Inc.	Methods for treating cancer
US11421011B2 (en)	2017-05-18	2022-08-23	Modernatx, Inc.	Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
CA3060618A1 (en)	2017-05-19	2018-11-22	Wuxi Biologics (Shanghai) Co. Ltd.	Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
MX2019014023A (es)	2017-05-24	2020-02-17	Novartis Ag	Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CN110719915A (zh)	2017-05-25	2020-01-21	百时美施贵宝公司	包含经修饰的重链恒定区的抗体
JP7416625B2 (ja)	2017-05-25	2024-01-17	アボット・ラボラトリーズ	早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
IL322104A (en)	2017-05-30	2025-09-01	Bristol Myers Squibb Co	Treatment of lag-3 positive tumors
AU2018275209A1 (en)	2017-05-30	2019-10-17	Bristol-Myers Squibb Company	Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
MX2019012038A (es)	2017-05-30	2019-11-18	Bristol Myers Squibb Co	Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
EP3631466A1 (en)	2017-05-30	2020-04-08	Abbott Laboratories	Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
WO2018225093A1 (en)	2017-06-07	2018-12-13	Glaxosmithkline Intellectual Property Development Limited	Chemical compounds as atf4 pathway inhibitors
US11572541B2 (en)	2017-06-09	2023-02-07	Providence Health & Services—Oregon	Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
CN111201035A (zh)	2017-06-19	2020-05-26	梅迪塞纳医疗股份有限公司	Il-2超激动剂、激动剂及其融合体的用途和方法
GB201709808D0 (en)	2017-06-20	2017-08-02	Kymab Ltd	Antibodies
EP3641739A1 (en)	2017-06-20	2020-04-29	Institut Curie	Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
MY198676A (en)	2017-06-22	2023-09-15	Celgene Corp	Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
US11312783B2 (en)	2017-06-22	2022-04-26	Novartis Ag	Antibody molecules to CD73 and uses thereof
EP3642240A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
TW201906865A (zh)	2017-06-28	2019-02-16	瑞士商諾華公司	預防及治療尿失禁之方法
LT3644999T (lt)	2017-06-30	2023-03-10	Celgene Corporation	2-(4-chlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il) metil)-2,2-difluoracetamido kompozicijos ir panaudojimo būdai
JP2020525512A (ja)	2017-07-03	2020-08-27	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物
JP7454945B2 (ja)	2017-07-03	2024-03-25	アボット・ラボラトリーズ	血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
EP3649106A1 (en)	2017-07-03	2020-05-13	GlaxoSmithKline Intellectual Property Development Limited	N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
CN107325181A (zh) *	2017-07-05	2017-11-07	无锡傲锐东源生物科技有限公司	抗ctla4蛋白单克隆抗体及其用途
TWI830576B (zh)	2017-07-10	2024-01-21	美商西建公司	抗增生化合物及其使用方法
JP7028953B2 (ja)	2017-07-11	2022-03-02	ファイザー・インク	Ｃｅａ、ｍｕｃ１およびｔｅｒｔを含む免疫原性組成物
WO2019014402A1 (en)	2017-07-14	2019-01-17	Innate Tumor Immunity, Inc.	MODULATORS OF NLRP3
US10894833B2 (en)	2017-07-20	2021-01-19	H. Lundbeck A/S	Agents, uses and methods for treatment
US11926664B2 (en)	2017-07-25	2024-03-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for modulating monocytopoiesis
TWI799432B (zh)	2017-07-27	2023-04-21	美商再生元醫藥公司	抗ctla-4抗體及其用途
WO2019021208A1 (en)	2017-07-27	2019-01-31	Glaxosmithkline Intellectual Property Development Limited	USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
SG11202000932XA (en)	2017-08-03	2020-02-27	Otsuka Pharma Co Ltd	Drug compound and purification methods thereof
US10508115B2 (en)	2017-08-16	2019-12-17	Bristol-Myers Squibb Company	Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en)	2017-08-16	2019-12-03	Bristol-Myers Squibb Company	Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en)	2017-08-16	2019-11-12	Bristol-Myers Squibb Company	Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
JP2020531430A (ja) *	2017-08-16	2020-11-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	抗体を標的とする抗ｃｔｌａ４プロボディ療法
US10457681B2 (en)	2017-08-16	2019-10-29	Bristol_Myers Squibb Company	Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en)	2017-08-16	2019-11-26	Bristol-Myers Squibb Company	Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US11745165B2 (en)	2017-08-18	2023-09-05	The Johns Hopkins University	Supramolecular filamentous assemblies for protein purification
TWI785098B (zh)	2017-08-18	2022-12-01	開曼群島商科賽睿生命科學公司	Tg02之多晶型
WO2019036855A1 (en)	2017-08-21	2019-02-28	Adagene Inc.	Anti-cd137 molecules and use thereof
UY37866A (es)	2017-09-07	2019-03-29	Glaxosmithkline Ip Dev Ltd	Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (en)	2017-09-12	2019-03-21	Glaxosmithkline Intellectual Property Development Limited	CHEMICAL COMPOUNDS
WO2019057744A1 (en)	2017-09-19	2019-03-28	Institut Curie	AROMATIC HYDROCARBON RECEPTOR AGONIST FOR USE IN ASSOCIATION TREATMENT AGAINST CANCER
AU2018336785B2 (en)	2017-09-20	2022-07-14	Regeneron Pharmaceuticals, Inc.	Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
KR102760684B1 (ko)	2017-09-29	2025-01-24	브리스톨-마이어스 스큅 컴퍼니	암을 치료하기 위한 조성물 및 방법
CN111417630B (zh)	2017-10-05	2023-06-06	葛兰素史克知识产权开发有限公司	干扰素基因刺激因子(sting)的调节剂
US20210238172A1 (en)	2017-10-05	2021-08-05	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides useful as protein modulators and methods of using the same
WO2019075385A1 (en)	2017-10-12	2019-04-18	Board Of Regents, The University Of Texas System	T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
KR102425983B1 (ko)	2017-10-13	2022-07-29	하푼 테라퓨틱스, 인크.	삼중특이적 단백질 및 사용 방법
CN111247169A (zh)	2017-10-15	2020-06-05	百时美施贵宝公司	治疗肿瘤的方法
US20210040205A1 (en)	2017-10-25	2021-02-11	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
EP3704159A1 (en)	2017-11-01	2020-09-09	Bristol-Myers Squibb Company	Immunostimulatory agonistic antibodies for use in treating cancer
KR20200085780A (ko)	2017-11-07	2020-07-15	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	암의 치료에서 car-t 또는 car-nk 세포를 사용한 lilrb4 표적화
JP7544598B2 (ja)	2017-11-10	2024-09-03	アーモ・バイオサイエンシーズ・インコーポレイテッド	免疫チェックポイント経路阻害剤と併用したインターロイキン－１０の組成物および使用方法
CA3082287C (en)	2017-11-14	2023-02-28	Pfizer Inc.	Ezh2 inhibitor combination therapies
CA3083158A1 (en)	2017-11-24	2019-05-31	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods and compositions for treating cancers
EP3717021A1 (en)	2017-11-27	2020-10-07	Mersana Therapeutics, Inc.	Pyrrolobenzodiazepine antibody conjugates
US11254980B1 (en)	2017-11-29	2022-02-22	Adaptive Biotechnologies Corporation	Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
WO2019113525A2 (en)	2017-12-09	2019-06-13	Abbott Laboratories	Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
CA3067055A1 (en)	2017-12-09	2019-06-13	Abbott Laboratories	Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
EP3498293A1 (en)	2017-12-15	2019-06-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Treatment of monogenic diseases with an anti-cd45rc antibody
JP2021506795A (ja)	2017-12-15	2021-02-22	ボードオブリージェンツ, ザユニバーシティオブテキサスシステムBoard Of Regents, The University Of Texas System	エキソソーム関連遺伝子編集を用いてがんを処置するための方法および組成物
EP3728314A1 (en)	2017-12-19	2020-10-28	Kymab Limited	Bispecific antibody for icos and pd-l1
GB201721338D0 (en)	2017-12-19	2018-01-31	Kymab Ltd	Anti-icos Antibodies
PL3710484T3 (pl) *	2017-12-20	2024-03-25	Harbour Biomed (Shanghai) Co., Ltd	Przeciwciała wiążące ctla-4 i ich zastosowania
EP3727463A1 (en)	2017-12-21	2020-10-28	Mersana Therapeutics, Inc.	Pyrrolobenzodiazepine antibody conjugates
CN111788227B (zh)	2017-12-27	2025-02-25	百时美施贵宝公司	抗cd40抗体及其用途
SG11202004158QA (en)	2017-12-28	2020-06-29	Nanjing Legend Biotech Co Ltd	Single-domain antibodies and variants thereof against tigit
JP2021508477A (ja)	2017-12-29	2021-03-11	オンコラス，インコーポレイテッド	治療用ポリペプチドの腫瘍溶解性ウイルス送達
JP2021510697A (ja)	2018-01-12	2021-04-30	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	がん処置のための坑ｉｌ−８抗体及び坑ｐｄ−１抗体を用いる組合せ治療
US12129297B2 (en)	2018-01-12	2024-10-29	Bristol-Myers Squibb Company	Antibodies against TIM3 and uses thereof
US12128018B2 (en)	2018-01-12	2024-10-29	KDAc Therapeutics, Inc.	Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer
CN111699200B (zh)	2018-01-15	2023-05-26	南京传奇生物科技有限公司	针对pd-1的单域抗体和其变体
US20210363242A1 (en)	2018-01-16	2021-11-25	Bristol-Myers Squibb Company	Methods of treating cancer with antibodies against tim3
KR20200112904A (ko)	2018-01-22	2020-10-05	브리스톨-마이어스 스큅 컴퍼니	암을 치료하는 조성물 및 방법
WO2019148445A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019160866A2 (en)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
CN119792515A (zh) *	2018-02-13	2025-04-11	默沙东有限责任公司	用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
US20210032334A1 (en)	2018-02-28	2021-02-04	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
CN111867679A (zh)	2018-03-06	2020-10-30	居里研究所	用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂
CN112218658A (zh)	2018-03-12	2021-01-12	国家健康科学研究所	热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
CN110272490B (zh) *	2018-03-14	2021-05-14	上海开拓者生物医药有限公司	靶向ctla-4抗体、其制备方法和用途
AU2019235842B2 (en)	2018-03-14	2022-02-03	Surface Oncology, Inc.	Antibodies that bind CD39 and uses thereof
CA3094329A1 (en)	2018-03-19	2020-02-20	Multivir Inc.	Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
CA3092589A1 (en)	2018-03-21	2019-09-26	Five Prime Therapeutics, Inc.	Antibodies binding to vista at acidic ph
US11242393B2 (en)	2018-03-23	2022-02-08	Bristol-Myers Squibb Company	Antibodies against MICA and/or MICB and uses thereof
US10760075B2 (en)	2018-04-30	2020-09-01	Snipr Biome Aps	Treating and preventing microbial infections
WO2019185551A1 (en)	2018-03-25	2019-10-03	Snipr Biome Aps.	Treating & preventing microbial infections
EP3773551B1 (en)	2018-03-27	2024-10-16	Board of Regents, The University of Texas System	Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
WO2019185792A1 (en)	2018-03-29	2019-10-03	Philogen S.P.A	Cancer treatment using immunoconjugates and immune check-point inhibitors
KR20200136464A (ko)	2018-03-29	2020-12-07	브리스톨-마이어스 스큅 컴퍼니	단량체성 모노클로날 항체를 정제하는 방법
WO2019191676A1 (en)	2018-03-30	2019-10-03	Bristol-Myers Squibb Company	Methods of treating tumor
WO2019193540A1 (en)	2018-04-06	2019-10-10	Glaxosmithkline Intellectual Property Development Limited	Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en)	2018-04-06	2019-10-10	Glaxosmithkline Intellectual Property Development Limited	Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
EP3775218A1 (en)	2018-04-09	2021-02-17	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
JOP20200242A1 (ar)	2018-04-09	2020-09-29	Eisai R&D Man Co Ltd	مركبات البلاديينوليد واستخداماتها
KR20250114141A (ko)	2018-04-12	2025-07-28	에자이 알앤드디 매니지먼트 가부시키가이샤	암을 치료하기 위한 스플라이세오솜 표적화제로서의 플라디에놀리드 유도체
WO2019209811A1 (en)	2018-04-24	2019-10-31	Bristol-Myers Squibb Company	Macrocyclic toll-like receptor 7 (tlr7) agonists
CA3097865A1 (en)	2018-04-25	2019-10-31	Innate Tumor Immunity, Inc.	Nlrp3 modulators
MX2020011176A (es)	2018-05-07	2020-11-12	Genmab As	Metodos para tratar cancer con una combinacion de un anticuerpo anti-molecula de muerte programada 1 y un conjugado de anticuerpo anti-factor tisular-medicamento.
SG11202010993VA (en)	2018-05-07	2020-12-30	Genmab As	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
GB201807924D0 (en)	2018-05-16	2018-06-27	Ctxt Pty Ltd	Compounds
BR112020023756A2 (pt)	2018-05-23	2021-02-09	Celgene Corporation	tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila
PL3796912T3 (pl)	2018-05-23	2023-09-11	Celgene Corporation	Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
MX2020012674A (es)	2018-05-29	2021-02-09	Bristol Myers Squibb Co	Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion.
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
TW202017569A (zh)	2018-05-31	2020-05-16	美商佩樂敦治療公司	用於抑制cd73之組合物及方法
AU2019277632A1 (en)	2018-05-31	2020-12-24	National Cancer Center Japan	Biomarker for judging efficacy of immune checkpoint inhibitor
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
KR20210016375A (ko)	2018-06-01	2021-02-15	에자이 알앤드디 매니지먼트 가부시키가이샤	스플라이싱 조절제 항체-약물 접합체 및 사용 방법
EP3802579A1 (en)	2018-06-01	2021-04-14	The Board of Trustees of the Leland Stanford Junior University	Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
GB201809050D0 (en)	2018-06-01	2018-07-18	E Therapeutics Plc	Modulators of tryptophan catabolism
AU2019279012A1 (en)	2018-06-01	2020-12-24	Eisai R&D Management Co., Ltd.	Methods of using splicing modulators
WO2019241358A2 (en)	2018-06-12	2019-12-19	The Regents Of The University Of California	Single-chain bispecific chimeric antigen receptors for the treatment of cancer
US20210254069A1 (en)	2018-06-15	2021-08-19	Mina Therapeutics Limited	Combination therapies comprising c/ebp alpha sarna
WO2019245817A1 (en)	2018-06-19	2019-12-26	Armo Biosciences, Inc.	Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
SG11202100096XA (en)	2018-07-09	2021-02-25	Five Prime Therapeutics Inc	Antibodies binding to ilt4
CA3105942A1 (en)	2018-07-09	2020-01-16	Glaxosmithkline Intellectual Property Development Limited	Chemical compounds
MX2021000213A (es)	2018-07-11	2021-03-25	Five Prime Therapeutics Inc	Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acidico.
EP3820992A2 (en)	2018-07-11	2021-05-19	Actym Therapeutics, Inc.	Engineered immunostimulatory bacterial strains and uses thereof
WO2020014583A1 (en)	2018-07-13	2020-01-16	Bristol-Myers Squibb Company	Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
CN112534052B (zh)	2018-07-25	2024-09-20	奥美药业有限公司	全新il-21前药及使用方法
US11554120B2 (en)	2018-08-03	2023-01-17	Bristol-Myers Squibb Company	1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020030634A1 (en)	2018-08-06	2020-02-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cancers
WO2020031107A1 (en)	2018-08-08	2020-02-13	Glaxosmithkline Intellectual Property Development Limited	Chemical compounds
JP2021534101A (ja)	2018-08-09	2021-12-09	ヴェルソーセラピューティクス，インコーポレイテッド	Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
SG11202101486RA (en)	2018-08-16	2021-03-30	Innate Tumor Immunity Inc	Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
EP3837014B1 (en)	2018-08-16	2022-10-19	Innate Tumor Immunity, Inc.	Imidazo[4,5-c]quinoline derived nlrp3-modulators
ES2974964T3 (es)	2018-08-16	2024-07-02	Innate Tumor Immunity Inc	Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina
EP3617230A1 (en)	2018-09-03	2020-03-04	BioInvent International AB	Novel antibodies and nucleotide sequences, and uses thereof
WO2020048942A1 (en)	2018-09-04	2020-03-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
WO2020049534A1 (en)	2018-09-07	2020-03-12	Novartis Ag	Sting agonist and combination therapy thereof for the treatment of cancer
WO2020061210A1 (en)	2018-09-18	2020-03-26	Merrimack Pharmaceuticals, Inc.	Anti-tnfr2 antibodies and uses thereof
US20220177587A1 (en)	2018-09-19	2022-06-09	Alpine Immune Sciences, Inc.	Methods and uses of variant cd80 fusion proteins and related constructs
WO2020058372A1 (en)	2018-09-19	2020-03-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
WO2020058762A1 (en) *	2018-09-20	2020-03-26	Tikcro Technologies Ltd	Antibodies specific to ctla-4 and uses thereof
US12269855B2 (en)	2018-09-21	2025-04-08	Innovent Biologics (Suzhou) Co., Ltd.	Interleukin-2 and use thereof
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
JP2022501009A (ja)	2018-09-21	2022-01-06	イノベントバイオロジックス（スウツォウ）カンパニー，リミテッド	新規インターロイキン２およびその使用
EP3856771A4 (en)	2018-09-25	2022-06-29	Harpoon Therapeutics, Inc.	Dll3 binding proteins and methods of use
US20200102370A1 (en)	2018-09-28	2020-04-02	Massachusetts Institute Of Technology	Collagen-localized immunomodulatory molecules and methods thereof
EP3860578A1 (en)	2018-10-01	2021-08-11	Institut National de la Santé et de la Recherche Médicale (INSERM)	Use of inhibitors of stress granule formation for targeting the regulation of immune responses
TW202446772A (zh)	2018-10-11	2024-12-01	日商小野藥品工業股份有限公司	Ｓｔｉｎｇ促效化合物
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
EP3867269A1 (en)	2018-10-18	2021-08-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
JP2022505647A (ja)	2018-10-23	2022-01-14	ブリストル－マイヤーズスクイブカンパニー	腫瘍の処置方法
CN113365664A (zh)	2018-10-29	2021-09-07	梅尔莎纳医疗公司	具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
TWI844571B (zh)	2018-10-30	2024-06-11	丹麥商珍美寶股份有限公司	使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
NZ775959A (en) *	2018-10-31	2022-08-26	Bioatla Inc	Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20220001026A1 (en)	2018-11-08	2022-01-06	Modernatx, Inc.	Use of mrna encoding ox40l to treat cancer in human patients
US20210405057A1 (en)	2018-11-09	2021-12-30	Pierian Biosciences, LLC	Methods and compositions for determining the composition of a tumor microenvironment
JP7520003B2 (ja)	2018-11-16	2024-07-22	ブリストル－マイヤーズスクイブカンパニー	抗ｎｋｇ２ａ抗体およびその使用
JP2022507606A (ja)	2018-11-16	2022-01-18	ネオイミューンテック，インコーポレイテッド	Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
WO2020102804A2 (en)	2018-11-16	2020-05-22	Arqule, Inc.	Pharmaceutical combination for treatment of cancer
CN113286813A (zh)	2018-11-19	2021-08-20	得克萨斯大学体系董事会	用于car和tcr转导的模块化多顺反子载体
US20220016277A1 (en)	2018-11-20	2022-01-20	Cornell University	Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
EP3886842A1 (en)	2018-11-26	2021-10-06	Debiopharm International SA	Combination treatment of hiv infections
WO2020111018A1 (ja)	2018-11-27	2020-06-04	小野薬品工業株式会社	免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療
KR20210096638A (ko)	2018-11-28	2021-08-05	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	억제성 환경에 대한 기능 및 내성을 증진시키기 위한 면역 세포의 멀티플렉스 게놈 편집
US20220018828A1 (en)	2018-11-28	2022-01-20	Inserm (Institut National De La Santé Et La Recherche Médicale	Methods and kit for assaying lytic potential of immune effector cells
CN113348177A (zh)	2018-11-28	2021-09-03	百时美施贵宝公司	包含经修饰的重链恒定区的抗体
EP4471129A3 (en)	2018-11-29	2025-02-19	Board of Regents, The University of Texas System	Methods for ex vivo expansion of natural killer cells and use thereof
TWI824069B (zh)	2018-11-30	2023-12-01	英商葛蘭素史密斯克藍智慧財產發展有限公司	用於hiv治療之化合物
ES2943474T3 (es)	2018-11-30	2023-06-13	Bristol Myers Squibb Co	Anticuerpo que comprende una extensión carboxiterminal de una cadena ligera que contiene glutamina, conjugados del mismo, y métodos y usos
JP7514834B2 (ja)	2018-12-03	2024-07-11	アジェンシス，インコーポレイテッド	抗１９１ｐ４ｄ１２抗体薬物コンジュゲートを含む薬学的組成物、およびその使用方法
WO2020115262A1 (en)	2018-12-07	2020-06-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
MA54448A (fr)	2018-12-11	2021-10-20	Theravance Biopharma R&D Ip Llc	Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
CN113544155A (zh)	2018-12-12	2021-10-22	百时美施贵宝公司	经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途
MX2021005878A (es)	2018-12-13	2021-07-16	Eisai R&D Man Co Ltd	Modulador de empalme de herboxidieno de conjugados de anticuerpo-farmaco y metodos de uso.
EP3897624A1 (en)	2018-12-17	2021-10-27	Institut National de la Santé et de la Recherche Médicale (INSERM)	Use of sulconazole as a furin inhibitor
BR112021012631A2 (pt)	2018-12-26	2021-12-14	Xilio Dev Inc	Anticorpos anti-ctla4 e métodos de uso dos mesmos
MX2021007639A (es)	2018-12-27	2021-08-11	Amgen Inc	Formulaciones de virus liofilizadas.
WO2020140084A1 (en) *	2018-12-27	2020-07-02	Gigagen, Inc.	Anti-ctla-4 binding proteins and methods of use thereof
CA3124773A1 (en)	2018-12-28	2020-07-02	Transgene	M2-defective poxvirus
SG11202107257UA (en)	2019-01-03	2021-07-29	Inst Nat Sante Rech Med	Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
EA202191903A1 (ru)	2019-01-09	2021-11-12	Селджин Корпорейшн	Антипролиферативные соединения и вторые активные агенты для комбинированного применения
MX2021008295A (es)	2019-01-09	2021-10-13	Celgene Corp	Formas sólidas que comprenden (s)-4-(4-(4-(((2-(2,6-dioxopiperidin -3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperazin-1-il)-3-fl uorobenzonitrilo y sales del mismo, composiciones que comprenden y métodos de utilización del mismo.
EA202191904A1 (ru)	2019-01-09	2021-10-04	Селджин Корпорейшн	Фармацевтические композиции, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и способы их применения
WO2020150113A1 (en)	2019-01-14	2020-07-23	Innate Tumor Immunity, Inc.	Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
US12338228B2 (en)	2019-01-14	2025-06-24	Innate Tumor Immunity, Inc.	NLRP3 modulators
KR102865929B1 (ko)	2019-01-14	2025-09-29	인네이트 튜머 이뮤니티, 인코포레이티드	Nlrp3 조정제
CN113301962A (zh)	2019-01-14	2021-08-24	先天肿瘤免疫公司	用于治疗癌症的杂环nlrp3调节剂
IL284868B2 (en)	2019-01-15	2025-09-01	Inst Nat Sante Rech Med	Mutant interleukin-34 (IL-34) polypeptides and their use for medical therapy
AU2020210635B2 (en)	2019-01-22	2024-12-12	Bristol Myers Squibb Company	Antibodies against IL-7R alpha subunit and uses thereof
WO2020154032A1 (en)	2019-01-23	2020-07-30	Massachusetts Institute Of Technology	Combination immunotherapy dosing regimen for immune checkpoint blockade
CN113795512A (zh)	2019-02-01	2021-12-14	葛兰素史克知识产权开发有限公司	包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法
WO2020169472A2 (en)	2019-02-18	2020-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of inducing phenotypic changes in macrophages
CA3131953A1 (en)	2019-03-01	2020-09-10	Merrimack Pharmaceuticals, Inc.	Anti-tnfr2 antibodies and uses thereof
US20220090133A1 (en)	2019-03-05	2022-03-24	Amgen Inc.	Use of oncolytic viruses for the treatment of cancer
US12358986B2 (en)	2019-03-13	2025-07-15	Merck Sharp & Dohme Llc	Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents
WO2020183011A1 (en)	2019-03-14	2020-09-17	Institut Curie	Htr1d inhibitors and uses thereof in the treatment of cancer
WO2020191084A1 (en)	2019-03-18	2020-09-24	The Regents Of The University Of California	Augmentation of t-cell activation by oscillatory forces and engineered antigen-presenting cells
CN114269763A (zh)	2019-03-26	2022-04-01	美国密歇根州立大学试剂中心	Stat3的小分子降解剂
CN113677402A (zh)	2019-03-28	2021-11-19	百时美施贵宝公司	治疗肿瘤的方法
US20220195046A1 (en)	2019-03-28	2022-06-23	Bristol-Myers Squibb Company	Methods of treating tumor
US20220185831A1 (en)	2019-03-29	2022-06-16	The Regents Of The University Of Michigan	Stat3 protein degraders
IL286711B2 (en)	2019-03-29	2025-10-01	Inst Curie	Interleukin 2 variants with different biological activities
TW202102543A (zh)	2019-03-29	2021-01-16	美商安進公司	溶瘤病毒在癌症新輔助療法中之用途
KR102829207B1 (ko)	2019-03-29	2025-07-02	브리스톨-마이어스 스큅 컴퍼니	크로마토그래피 수지의 소수성을 측정하는 방법
WO2020201362A2 (en)	2019-04-02	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
EP3947640A4 (en)	2019-04-02	2022-12-14	The Brigham & Women's Hospital, Inc.	PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
US20220160692A1 (en)	2019-04-09	2022-05-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
EP3956446A1 (en)	2019-04-17	2022-02-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
US12478674B2 (en)	2019-04-18	2025-11-25	Bristol-Myers Squibb Company	Ipilimumab variants with enhanced specificity for binding at low pH
US12492380B2 (en)	2019-05-09	2025-12-09	FUJIFILM Cellular Dynamics, Inc.	Methods for the production of hepatocytes
EP3969452A1 (en)	2019-05-16	2022-03-23	Stingthera, Inc.	Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
CN114302875A (zh)	2019-05-16	2022-04-08	斯汀塞拉股份有限公司	氧代吖啶基乙酸衍生物及使用方法
US10945981B2 (en)	2019-05-17	2021-03-16	Cancer Prevention Pharmaceuticals, Inc.	Methods for treating familial adenomatous polyposis
JP2022533791A (ja)	2019-05-20	2022-07-25	マサチューセッツインスティテュートオブテクノロジー	ボロン酸エステルプロドラッグおよびそれらの使用
EP3976832A1 (en)	2019-05-30	2022-04-06	Bristol-Myers Squibb Company	Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
JP2022534967A (ja)	2019-05-30	2022-08-04	ブリストル－マイヤーズスクイブカンパニー	多腫瘍遺伝子シグネチャーおよびその使用
KR20220016157A (ko)	2019-05-30	2022-02-08	브리스톨-마이어스 스큅 컴퍼니	세포 국재화 시그너쳐 및 조합 요법
CA3144535A1 (en)	2019-06-03	2020-12-10	The University Of Chicago	Methods and compositions for treating cancer with collagen binding drug carriers
AU2020286523A1 (en)	2019-06-03	2022-02-03	The University Of Chicago	Methods and compositions for treating cancer with cancer-targeted adjuvants
US11246906B2 (en)	2019-06-11	2022-02-15	Alkermes Pharma Ireland Limited	Compositions and methods for subcutaneous administration of cancer immunotherapy
US11845801B2 (en)	2019-06-12	2023-12-19	AskGene Pharma, Inc.	IL-15 prodrugs and methods of use thereof
AU2020291936A1 (en)	2019-06-12	2022-02-03	Vanderbilt University	Dibenzylamines as amino acid transport inhibitors
WO2020252353A1 (en)	2019-06-12	2020-12-17	Vanderbilt University	Amino acid transport inhibitors and the uses thereof
KR20220026585A (ko)	2019-06-26	2022-03-04	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	Il1rap 결합 단백질
US11642409B2 (en)	2019-06-26	2023-05-09	Massachusetts Insttute of Technology	Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP3990618A4 (en)	2019-06-27	2023-08-09	The George Washington University, A Congressionally Chartered Not-For-Profit Corporation	HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS AND ASSOCIATED USES
SG11202111943UA (en)	2019-07-02	2021-11-29	Hutchinson Fred Cancer Res	Recombinant ad35 vectors and related gene therapy improvements
AU2020315401B2 (en)	2019-07-16	2025-05-22	The Regents Of The University Of Michigan	Imidazopyrimidines as EED inhibitors and the use thereof
GB201910304D0 (en)	2019-07-18	2019-09-04	Ctxt Pty Ltd	Compounds
GB201910305D0 (en)	2019-07-18	2019-09-04	Ctxt Pty Ltd	Compounds
CN114144436A (zh)	2019-07-24	2022-03-04	H.隆德贝克有限公司	抗mGluR5抗体及其用途
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP3778875A1 (en)	2019-08-14	2021-02-17	MaxiVax SA	Immortalized myoblast cell lines and uses thereof
US11851490B2 (en)	2019-08-15	2023-12-26	Northwestern University	Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
GB201912107D0 (en)	2019-08-22	2019-10-09	Amazentis Sa	Combination
JP2022545735A (ja)	2019-08-27	2022-10-28	ザリージェンツオブザユニヴァシティオブミシガン	セレブロンｅ３リガーゼ阻害剤
WO2021043961A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046289A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
US11655303B2 (en)	2019-09-16	2023-05-23	Surface Oncology, Inc.	Anti-CD39 antibody compositions and methods
WO2021055306A1 (en)	2019-09-16	2021-03-25	Bristol-Myers Squibb Company	Dual capture method for analysis of antibody-drug conjugates
CN114901652A (zh)	2019-09-17	2022-08-12	比亚尔R&D投资股份公司	用于治疗医学病症的经取代的饱和和不饱和n-杂环甲酰胺及相关化合物
CA3150700A1 (en)	2019-09-17	2021-03-25	Renato T. Skerlj	IMIDAZOLE SUBSTITUTE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
AU2020349519A1 (en)	2019-09-17	2022-03-17	Bial-R&D Investments, S.A.	Substituted N-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
BR112022004831A2 (pt)	2019-09-19	2022-06-07	Bristol Myers Squibb Co	Anticorpos que se ligam a vista em ph ácido
AU2020348849A1 (en)	2019-09-19	2022-04-07	The Regents Of The University Of Michigan	Spirocyclic androgen receptor protein degraders
CN114450028A (zh)	2019-09-22	2022-05-06	百时美施贵宝公司	Lag-3拮抗剂治疗的定量空间剖析
WO2021061789A1 (en)	2019-09-23	2021-04-01	The Regents Of The University Of Michigan	Compositions and methods for increasing the efficacy of immunotherapies and vaccines
TWI764291B (zh)	2019-09-24	2022-05-11	財團法人工業技術研究院	抗tigit抗體及使用方法
TW202521984A (zh)	2019-09-25	2025-06-01	美商表面腫瘤學有限責任公司	抗ｉｌ－２７抗體及其用途
EP3800201A1 (en)	2019-10-01	2021-04-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cd28h stimulation enhances nk cell killing activities
WO2021064184A1 (en)	2019-10-04	2021-04-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
US20220401539A1 (en)	2019-10-22	2022-12-22	Institut Curie	Immunotherapy Targeting Tumor Neoantigenic Peptides
US11459389B2 (en)	2019-10-24	2022-10-04	Massachusetts Institute Of Technology	Monoclonal antibodies that bind human CD161
KR20220088425A (ko)	2019-10-25	2022-06-27	다이이찌 산쿄 가부시키가이샤	항 garp 항체와 면역 조절제의 조합
NL2024108B1 (en)	2019-10-26	2021-07-19	Vitroscan B V	Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses
NL2024107B1 (en)	2019-10-26	2021-07-19	Vitroscan B V	Compositions for Patient Specific Immunotherapy
US12514927B2 (en)	2019-10-30	2026-01-06	Duke University	Immunotherapy with combination therapy comprising an immunotoxin
US20220380765A1 (en)	2019-11-02	2022-12-01	Board Of Regents, The University Of Texas System	Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
BR112022008557A2 (pt)	2019-11-04	2022-08-09	Seagen Inc	Conjugados de anticorpo-fármaco anti-cd30 e seu uso para o tratamento de infecção por hiv
JP2022554346A (ja)	2019-11-05	2022-12-28	セルジーンコーポレーション	２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法
WO2021092220A1 (en)	2019-11-06	2021-05-14	Bristol-Myers Squibb Company	Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en)	2019-11-06	2021-05-14	Bristol-Myers Squibb Company	Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
TW202132343A (zh)	2019-11-07	2021-09-01	丹麥商珍美寶股份有限公司	使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
TW202131954A (zh)	2019-11-07	2021-09-01	丹麥商珍美寶股份有限公司	利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
JP2022553851A (ja)	2019-11-08	2022-12-26	ブリストル－マイヤーズスクイブカンパニー	黒色腫の処置のためのｌａｇ－３アンタゴニスト
EP4058593A4 (en)	2019-11-12	2023-11-15	Foundation Medicine, Inc.	METHODS FOR DETECTING A FUSION GENE ENCODING A NEO-ANTIGEN
EP4058150A2 (en) *	2019-11-15	2022-09-21	Genzyme Corporation	Biparatopic cd73 antibodies
TW202132297A (zh)	2019-11-22	2021-09-01	美商施萬生物製藥研發Ｉｐ有限責任公司	經取代吡啶及使用方法
EP3824954A1 (en)	2019-11-22	2021-05-26	Centre National de la Recherche Scientifique	Device, apparatus and method for minibeam radiation therapy
AU2020394122A1 (en)	2019-11-27	2022-06-09	Nec Corporation	Pharmaceutical composition
WO2021113644A1 (en)	2019-12-05	2021-06-10	Multivir Inc.	Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CA3164751A1 (en)	2019-12-18	2021-06-24	Benjamin Joseph MORROW	Compounds
KR20220118481A (ko)	2019-12-19	2022-08-25	브리스톨-마이어스 스큅 컴퍼니	Dgk 억제제 및 체크포인트 길항제의 조합물
MY202559A (en)	2019-12-27	2024-05-08	Chugai Pharmaceutical Co Ltd	Anti-ctla-4 antibody and use thereof
JP2023509516A (ja)	2020-01-07	2023-03-08	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
CN115244052A (zh)	2020-01-10	2022-10-25	先天肿瘤免疫公司	Nlrp3调节剂
JP2023510854A (ja)	2020-01-13	2023-03-15	武田薬品工業株式会社	小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用
CN115362168A (zh)	2020-01-14	2022-11-18	辛德凯因股份有限公司	偏向化il2突变蛋白方法和组合物
CN115038466A (zh)	2020-01-28	2022-09-09	葛兰素史密斯克莱知识产权发展有限公司	联合治疗及其用途和方法
CA3166295A1 (en)	2020-01-29	2021-08-05	John Heymach	Use of poziotinib for the treatment of cancers with nrg1 fusions
US20230112470A1 (en)	2020-01-29	2023-04-13	Board Of Regents, The University Of Texas System	Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusions
JP2023514152A (ja)	2020-02-06	2023-04-05	ブリストル－マイヤーズスクイブカンパニー	Ｉｌ－１０およびその使用
US20230106973A1 (en)	2020-02-17	2023-04-06	Board Of Regents, The University Of Texas System	Methods for expansion of tumor infiltrating lymphocytes and use thereof
KR20220150353A (ko)	2020-03-05	2022-11-10	네오티엑스 테라퓨틱스 엘티디.	면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
US20230140384A1 (en)	2020-03-09	2023-05-04	Bristol-Myers Squibb Company	Antibodies to cd40 with enhanced agonist activity
US20230093147A1 (en)	2020-03-09	2023-03-23	President And Fellows Of Harvard College	Methods and compositions relating to improved combination therapies
EP3878446A1 (en)	2020-03-09	2021-09-15	Universite De Geneve	Hsd11b1 inhibitors for use in immunotherapy and uses thereof
US12522623B2 (en)	2020-03-26	2026-01-13	Regents Of The University Of Michigan	Small molecule STAT protein degraders
AU2021243864A1 (en)	2020-03-27	2022-11-03	Mendus B.V.	Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
TW202204339A (zh)	2020-03-31	2022-02-01	美商施萬生物製藥研發 Ip有限責任公司	經取代的嘧啶及使用方法
US20230141284A1 (en)	2020-04-10	2023-05-11	Ono Pharmaceutical Co., Ltd.	Cancer therapeutic method
WO2021205631A1 (ja)	2020-04-10	2021-10-14	小野薬品工業株式会社	Ｓｔｉｎｇ作動化合物
WO2021211331A1 (en)	2020-04-13	2021-10-21	Abbott Point Of Care Inc.	METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
WO2021216572A1 (en)	2020-04-20	2021-10-28	Massachusetts Institute Of Technology	Lipid compositions for delivery of sting agonist compounds and uses thereof
CA3175499A1 (en)	2020-04-21	2021-10-28	University Of Rochester	Inhibitors of human epididymus protein 4
US12159700B2 (en)	2020-04-22	2024-12-03	Iovance Biotherapeutics, Inc.	Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4143224A1 (en)	2020-05-01	2023-03-08	Novartis AG	Immunoglobulin variants
EP4143236A1 (en)	2020-05-01	2023-03-08	Novartis AG	Engineered immunoglobulins
WO2021224186A1 (en)	2020-05-04	2021-11-11	Institut Curie	New pyridine derivatives as radiosensitizers
WO2021231798A1 (en)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CA3177717A1 (en)	2020-05-13	2021-11-18	Adagene Ag	Compositions and methods for treating cancer
WO2021231732A1 (en)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Antibodies to garp
JP2023528293A (ja)	2020-05-20	2023-07-04	アンスティテュ・クリー	単一ドメイン抗体及びがん治療におけるその使用
EP4153301A2 (en)	2020-05-21	2023-03-29	Board of Regents, The University of Texas System	T cell receptors with vgll1 specificity and uses thereof
WO2021238932A1 (zh) *	2020-05-26	2021-12-02	百奥泰生物制药股份有限公司	多特异性抗体及其应用
EP4157319A1 (en)	2020-05-28	2023-04-05	Modernatx, Inc.	Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
US20230173095A1 (en)	2020-05-29	2023-06-08	President And Fellows Of Harvard College	Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
WO2021245071A1 (en)	2020-06-03	2021-12-09	Mv Biotherapeutics Sa	Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
WO2021247836A1 (en)	2020-06-03	2021-12-09	Board Of Regents, The University Of Texas System	Methods for targeting shp-2 to overcome resistance
EP4165041A1 (en)	2020-06-10	2023-04-19	Theravance Biopharma R&D IP, LLC	Naphthyridine derivatives useful as alk5 inhibitors
US20230293530A1 (en)	2020-06-24	2023-09-21	Yeda Research And Development Co. Ltd.	Agents for sensitizing solid tumors to treatment
CA3182867A1 (en)	2020-06-25	2021-12-30	Aarif Ahsan	Methods for treating cancer with combination therapies
KR20230028492A (ko)	2020-06-29	2023-02-28	젠맵 에이/에스	항-조직 인자 항체-약물 접합체 및 암의 치료에서의 그의 용도
CA3182607A1 (en)	2020-06-30	2022-01-06	Erik Hans MANTING	Use of leukemia-derived cells in ovarian cancer vaccines
WO2022002873A1 (en)	2020-06-30	2022-01-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
JP7741831B2 (ja)	2020-06-30	2025-09-18	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
WO2022003156A1 (en)	2020-07-02	2022-01-06	Oncurious Nv	Ccr8 non-blocking binders
WO2022010847A1 (en)	2020-07-07	2022-01-13	Cancure, Llc	Mic antibodies and binding agents and methods of using the same
DK4178548T3 (da)	2020-07-07	2024-08-19	Celgene Corp	Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL
US20250262293A1 (en)	2020-07-07	2025-08-21	BioNTech SE	Therapeutic rna for hpv-positive cancer
WO2022011205A1 (en)	2020-07-10	2022-01-13	The Regents Of The University Of Michigan	Androgen receptor protein degraders
WO2022011204A1 (en)	2020-07-10	2022-01-13	The Regents Of The University Of Michigan	Small molecule androgen receptor protein degraders
WO2022017428A1 (zh)	2020-07-21	2022-01-27	上海君实生物医药科技股份有限公司	抗ctla-4抗体及其用途
US20230295146A1 (en)	2020-07-24	2023-09-21	The University Of Rochester	Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
EP4193149A1 (en)	2020-08-04	2023-06-14	Abbott Laboratories	Improved methods and kits for detecting sars-cov-2 protein in a sample
WO2022029494A1 (en)	2020-08-04	2022-02-10	Abbott Rapid Diagnostics International Unlimited Company	Assays for detecting sars-cov-2
JP2023534765A (ja)	2020-08-07	2023-08-10	フォーティスセラピューティクス，インク．	免疫複合体を標的とするｃｄ４６およびその使用方法
AU2021331476A1 (en)	2020-08-28	2023-05-04	Bristol-Myers Squibb Company	Lag-3 antagonist therapy for hepatocellular carcinoma
US20230303700A1 (en)	2020-08-31	2023-09-28	Bristol-Myers Squibb Company	Cell localization signature and immunotherapy
CN116601140A (zh)	2020-10-02	2023-08-15	羿尊生物医药股份有限公司	用于皮下施用的包含(s)-2-((s)-2-乙酰氨基-3-(1h-吲哚-3-基)丙酰氨基)-6-重氮基-5-氧代己酸异丙酯的冻干组合物及其用途
EP4229090A1 (en)	2020-10-16	2023-08-23	Université d'Aix-Marseille	Anti-gpc4 single domain antibodies
US20230303604A1 (en)	2020-10-20	2023-09-28	Institut Curie	Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
MX2023004493A (es)	2020-10-23	2023-05-10	Bristol Myers Squibb Co	Terapia de agonista del gen-3 de activacion del linfocito (lag-3) para cancer de pulmon.
CA3195572A1 (en)	2020-11-04	2022-05-12	Heidelberg Pharma Research Gmbh	Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy
US20240009241A1 (en)	2020-11-05	2024-01-11	Board Of Regents, The University Of Texas System	Engineered t cell receptors targeting egfr antigens and methods of use
WO2022097065A2 (en)	2020-11-06	2022-05-12	Novartis Ag	ANTIBODY Fc VARIANTS
CA3200974A1 (en)	2020-11-08	2022-05-12	Seagen Inc.	Combination therapy
TW202228674A (zh)	2020-11-13	2022-08-01	日商小野藥品工業股份有限公司	藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療
WO2022104109A1 (en)	2020-11-13	2022-05-19	Catamaran Bio, Inc.	Genetically modified natural killer cells and methods of use thereof
JP2023549581A (ja)	2020-11-17	2023-11-27	シージェンインコーポレイテッド	ツカチニブ及び抗ｐｄ－１／抗ｐｄ－ｌ１抗体の組み合わせによりがんを治療する方法
WO2022106505A1 (en)	2020-11-18	2022-05-27	Institut Curie	Dimers of biguanidines and their therapeutic uses
EP4251645A1 (en)	2020-11-25	2023-10-04	Catamaran Bio, Inc.	Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2023102384A1 (en)	2021-11-30	2023-06-08	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022119841A1 (en)	2020-12-01	2022-06-09	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022120179A1 (en)	2020-12-03	2022-06-09	Bristol-Myers Squibb Company	Multi-tumor gene signatures and uses thereof
PH12023500013A1 (en)	2020-12-04	2024-03-11	Tidal Therapeutics Inc	Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
EP4259661A1 (en)	2020-12-14	2023-10-18	Novartis AG	Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
WO2022130206A1 (en)	2020-12-16	2022-06-23	Pfizer Inc.	TGFβr1 INHIBITOR COMBINATION THERAPIES
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
WO2022136650A1 (en)	2020-12-24	2022-06-30	Oncurious Nv	Murine cross-reactive human ccr8 binders
CA3206124A1 (en)	2020-12-24	2022-06-30	Vib Vzw	Non-blocking human ccr8 binders
EP4267617A1 (en)	2020-12-24	2023-11-01	Vib Vzw	Human ccr8 binders
MX2023007650A (es)	2020-12-28	2023-09-11	Bristol Myers Squibb Co	Metodos de tratamiento de tumores.
MX2023007734A (es)	2020-12-28	2023-08-21	Bristol Myers Squibb Co	Composiciones de anticuerpos y metodos de uso de las mismas.
WO2022147147A1 (en)	2020-12-30	2022-07-07	Abbott Laboratories	Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
CA3204162A1 (en)	2021-01-11	2022-07-14	Robert Kastelein	Compositions and methods related to receptor pairing
JP2024505428A (ja)	2021-01-14	2024-02-06	アンスティテュキュリー	Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ
WO2022159492A1 (en)	2021-01-19	2022-07-28	William Marsh Rice University	Bone-specific delivery of polypeptides
WO2022159575A1 (en) *	2021-01-20	2022-07-28	Bioentre Llc	Ctla4-binding proteins and methods of treating cancer
AU2022211682A1 (en)	2021-01-22	2023-08-03	Mendus B.V.	Methods of tumor vaccination
WO2022165214A1 (en)	2021-01-29	2022-08-04	Board Of Regents, The University Of Texas System	Methods of treating cancer with kinase inhibitors
CA3206549A1 (en)	2021-01-29	2022-08-04	Frederick G. Vogt	Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
US20240166647A1 (en)	2021-03-03	2024-05-23	The Regents Of The University Of Michigan	Cereblon Ligands
WO2022187419A1 (en)	2021-03-03	2022-09-09	The Regents Of The University Of Michigan	Small molecule degraders of androgen receptor
WO2022189618A1 (en)	2021-03-12	2022-09-15	Institut Curie	Nitrogen-containing heterocycles as radiosensitizers
WO2022190058A1 (en)	2021-03-12	2022-09-15	Dcprime B.V.	Methods of vaccination and use of cd47 blockade
JP2024514530A (ja)	2021-04-02	2024-04-02	ザリージェンツオブザユニバーシティオブカリフォルニア	切断型ｃｄｃｐ１に対する抗体およびその使用
EP4319755A4 (en)	2021-04-08	2025-03-26	Board of Regents, The University of Texas System	Compounds and methods for theranostic targeting of parp activity
EP4070799A1 (en)	2021-04-08	2022-10-12	Nuvamid SA	Compositions for the improvement of sport performance
AU2022253902A1 (en)	2021-04-10	2023-11-02	Genmab A/S	Folr1 binding agents, conjugates thereof and methods of using the same
EP4079311B1 (en)	2021-04-20	2025-10-01	Nuvamid SA	Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
EP4079310A1 (en)	2021-04-20	2022-10-26	Nuvamid SA	Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
JP7742892B2 (ja)	2021-04-23	2025-09-22	ジェンマブエー／エス	抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
EP4329734A4 (en)	2021-04-26	2025-04-02	Celanese EVA Performance Polymers LLC	Implantable device for the delayed release of a macromolecular drug compound
EP4329777A1 (en)	2021-04-28	2024-03-06	MiNA Therapeutics Limited	Combination therapies comprising c/ebp alpha sarna
EP4337763A1 (en)	2021-05-10	2024-03-20	Institut Curie	Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
CA3216320A1 (en)	2021-05-18	2022-11-24	Abbott Laboratories	Methods of evaluating brain injury in a pediatric subject
WO2022251359A1 (en)	2021-05-26	2022-12-01	Theravance Biopharma R&D Ip, Llc	Bicyclic inhibitors of alk5 and methods of use
AU2022288058A1 (en)	2021-06-07	2023-11-16	Agonox, Inc.	Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022260132A1 (ja)	2021-06-10	2022-12-15	小野薬品工業株式会社	Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法
WO2022266034A1 (en)	2021-06-14	2022-12-22	Abbott Laboratories	Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
CR20240026A (es)	2021-06-25	2024-03-14	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-ctla-4
AU2022297107B2 (en)	2021-06-25	2024-08-01	Chugai Seiyaku Kabushiki Kaisha	Use of anti-ctla-4 antibody
US12448451B2 (en)	2021-06-25	2025-10-21	Chugai Seiyaku Kabushiki Kaisha	Anti-CTLA-4 antibody and use thereof
WO2023280790A1 (en)	2021-07-05	2023-01-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
CA3225254A1 (en)	2021-07-13	2023-01-19	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
JP2024529340A (ja)	2021-07-14	2024-08-06	シンセカインインコーポレイテッド	新生物疾患の細胞療法に使用するための方法および組成物
US20250114452A1 (en)	2021-08-04	2025-04-10	The Regents Of The University Of Colorado, A Body Corporate	Lat activating chimeric antigen receptor t cells and methods of use thereof
US20250135232A1 (en)	2021-08-05	2025-05-01	Institut Curie	Scanning dynamic device for minibeams production
CA3229448A1 (en)	2021-08-23	2023-03-02	Immunitas Therapeutics, Inc.	Anti-cd161 antibodies and uses thereof
CN118715440A (zh)	2021-08-31	2024-09-27	雅培实验室	诊断脑损伤的方法和系统
AU2022339759A1 (en)	2021-08-31	2024-03-07	Abbott Laboratories	Methods and systems of diagnosing brain injury
US20240316061A1 (en)	2021-09-17	2024-09-26	Institut Curie	Bet inhibitors for treating pab1 deficient cancer
WO2023056268A1 (en)	2021-09-30	2023-04-06	Abbott Laboratories	Methods and systems of diagnosing brain injury
WO2023060136A1 (en)	2021-10-05	2023-04-13	Cytovia Therapeutics, Llc	Natural killer cells and methods of use thereof
TW202333802A (zh)	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
WO2023068382A2 (en)	2021-10-20	2023-04-27	Takeda Pharmaceutical Company Limited	Compositions targeting bcma and methods of use thereof
JP2024539139A (ja)	2021-10-20	2024-10-28	シンセカインインコーポレイテッド	ヘテロ二量体ｆｃサイトカインおよびその使用
WO2023076880A1 (en)	2021-10-25	2023-05-04	Board Of Regents, The University Of Texas System	Foxo1-targeted therapy for the treatment of cancer
EP4423249A1 (en)	2021-10-28	2024-09-04	Lyell Immunopharma, Inc.	Methods for culturing immune cells
AU2022375806A1 (en)	2021-10-29	2023-12-14	Bristol-Myers Squibb Company	Lag-3 antagonist therapy for hematological cancer
AU2022377628A1 (en)	2021-10-29	2024-04-11	Seagen Inc.	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
CN113907045B (zh) *	2021-11-09	2023-01-06	派生特（福州）生物科技有限公司	一种新品系猪的培育方法及其应用
EP4433096A1 (en)	2021-11-19	2024-09-25	Ardeagen Corporation	Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023089032A1 (en)	2021-11-19	2023-05-25	Institut Curie	Methods for the treatment of hrd cancer and brca-associated cancer
KR20240123846A (ko) *	2021-11-24	2024-08-14	다나-파버 캔서 인스티튜트 인크.	Ctla-4에 대한 항체 및 이의 사용 방법
WO2023099763A1 (en)	2021-12-03	2023-06-08	Institut Curie	Sirt6 inhibitors for use in treating resistant hrd cancer
AU2022413677A1 (en)	2021-12-17	2024-06-27	Abbott Laboratories	Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
CN119836296A (zh)	2021-12-30	2025-04-15	新免疫技术有限公司	用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法
JP2025503962A (ja)	2022-01-26	2025-02-06	ブリストル－マイヤーズスクイブカンパニー	肝細胞がんのための併用療法
JP2025504908A (ja)	2022-01-28	2025-02-19	アイオバンスバイオセラピューティクス，インコーポレイテッド	サイトカイン関連腫瘍浸潤リンパ球組成物及び方法
JP2025507303A (ja)	2022-02-04	2025-03-18	アボット・ラボラトリーズ	試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
WO2023154799A1 (en)	2022-02-14	2023-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Combination immunotherapy for treating cancer
US20230277669A1 (en)	2022-02-24	2023-09-07	Amazentis Sa	Uses of urolithins
AU2023226078A1 (en)	2022-02-25	2024-08-22	Bristol-Myers Squibb Company	Combination therapy for colorectal carcinoma.
WO2023168404A1 (en)	2022-03-04	2023-09-07	Bristol-Myers Squibb Company	Methods of treating a tumor
JP2025508076A (ja)	2022-03-08	2025-03-21	アレンティス・セラピューティクス・アクチェンゲゼルシャフト	Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
MX2024011278A (es)	2022-03-15	2024-09-25	Compugen Ltd	Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
KR20240161968A (ko)	2022-03-16	2024-11-13	다이이찌 산쿄 가부시키가이샤	다중 특이적 분자와 면역 체크 포인트 저해제의 조합
WO2023178329A1 (en)	2022-03-18	2023-09-21	Bristol-Myers Squibb Company	Methods of isolating polypeptides
EP4499134A1 (en)	2022-03-24	2025-02-05	Institut Curie	Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
US20250213614A1 (en)	2022-03-31	2025-07-03	Institut Curie	Modified RELA Protein for Inducing Interferon Expression and Engineered Immune Cells with Improved Interferon Expression
WO2023196988A1 (en)	2022-04-07	2023-10-12	Modernatx, Inc.	Methods of use of mrnas encoding il-12
EP4504244A1 (en)	2022-04-07	2025-02-12	Institut Curie	Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2023196987A1 (en)	2022-04-07	2023-10-12	Bristol-Myers Squibb Company	Methods of treating tumor
US20250241949A1 (en)	2022-04-07	2025-07-31	Institut Curie	Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
EP4507704A1 (en)	2022-04-15	2025-02-19	Iovance Biotherapeutics, Inc.	Til expansion processes using specific cytokine combinations and/or akti treatment
CA3255838A1 (en)	2022-04-26	2023-11-02	Novartis Ag	MULTISPECIFIC ANTIBODIES TARGETTING IL-13 AND IL-18
US20250235478A1 (en)	2022-04-28	2025-07-24	Musc Foundation For Research Development	Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023213764A1 (en)	2022-05-02	2023-11-09	Transgene	Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en)	2022-05-02	2023-11-09	Transgene	Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
TW202408583A (zh)	2022-05-06	2024-03-01	丹麥商珍美寶股份有限公司	使用抗組織因子抗體－藥物共軛體以治療癌症之方法
KR20250012631A (ko)	2022-05-24	2025-01-24	다이이찌 산쿄 가부시키가이샤	항-cdh6 항체-약물 접합체의 투약
AR129423A1 (es)	2022-05-27	2024-08-21	Viiv Healthcare Co	Compuestos útiles en la terapia contra el hiv
CA3258064A1 (en)	2022-06-02	2023-12-07	Bristol-Myers Squibb Company	ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
EP4536627A1 (en)	2022-06-08	2025-04-16	Tidal Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2023240287A1 (en)	2022-06-10	2023-12-14	Bioentre Llc	Combinations of ctla4 binding proteins and methods of treating cancer
AU2023298134A1 (en)	2022-06-29	2024-11-28	Abbott Laboratories	Magnetic point-of-care systems and assays for determining gfap in biological samples
GB202209518D0 (en)	2022-06-29	2022-08-10	Snipr Biome Aps	Treating & preventing E coli infections
CA3260559A1 (en)	2022-07-01	2024-01-04	Transgene	Fusion protein comprising a surfactant D protein and a component of TNFSF
KR20250040960A (ko)	2022-07-28	2025-03-25	아스트라제네카 유케이 리미티드	항체-약물 접합체 및 이중특이적 체크포인트 억제제의 조합
WO2024028794A1 (en)	2022-08-02	2024-02-08	Temple Therapeutics BV	Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024040175A1 (en)	2022-08-18	2024-02-22	Pulmatrix Operating Company, Inc.	Methods for treating cancer using inhaled angiogenesis inhibitor
IL318949A (en)	2022-08-23	2025-04-01	Ono Pharmaceutical Co	Bispecific antibody
CN117618555A (zh) *	2022-08-31	2024-03-01	百奥泰生物制药股份有限公司	抗tigit抗体和抗ctla-4抗体联合用于治疗肿瘤中的应用
WO2024052356A1 (en)	2022-09-06	2024-03-14	Institut National de la Santé et de la Recherche Médicale	Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
JP2025532597A (ja)	2022-09-15	2025-10-01	アボット・ラボラトリーズ	軽度及び超軽度の外傷性脳損傷を区別するためのバイオマーカー及び方法
EP4593868A1 (en)	2022-09-26	2025-08-06	Institut Curie	Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
WO2024086827A2 (en)	2022-10-20	2024-04-25	Repertoire Immune Medicines, Inc.	Cd8 t cell targeted il2
CN120018842A (zh)	2022-10-20	2025-05-16	国家医疗保健研究所	用于治疗癌症的联合疗法
KR20250099224A (ko)	2022-11-01	2025-07-01	하이델베르크 파마 리서치 게엠베하	항-gucy2c 항체 및 이의 용도
KR20250089492A (ko)	2022-11-07	2025-06-18	네오이뮨텍, 인코퍼레이티드	비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
EP4623072A2 (en)	2022-11-21	2025-10-01	Iovance Biotherapeutics, Inc.	Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
IL321098A (en)	2022-12-14	2025-07-01	Astellas Pharma Europe Bv	Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
KR20250123912A (ko)	2022-12-21	2025-08-18	브리스톨-마이어스 스큅 컴퍼니	폐암에 대한 병용 요법
EP4658687A1 (en)	2023-01-31	2025-12-10	University of Rochester	Immune checkpoint blockade therapy for treating staphylococcus aureus infections
KR20250152101A (ko)	2023-03-13	2025-10-22	하이델베르크 파마 리서치 게엠베하	암 치료에의 사용을 위한 피하 투여 항체-약물 접합체
WO2024196952A1 (en)	2023-03-20	2024-09-26	Bristol-Myers Squibb Company	Tumor subtype assessment for cancer therapy
WO2024194401A1 (en)	2023-03-21	2024-09-26	Institut Curie	Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en)	2023-03-21	2024-09-26	Institut Curie	Methods for the treatment of dedifferentiated liposarcoma
WO2024194402A1 (en)	2023-03-21	2024-09-26	Institut Curie	Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
KR20250164708A (ko)	2023-03-29	2025-11-25	다이이찌 산쿄 가부시키가이샤	항 cd25 항체 및 항 cd25 항체-약물 콘주게이트
WO2024211475A1 (en)	2023-04-04	2024-10-10	Abbott Laboratories	Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024213782A1 (en)	2023-04-13	2024-10-17	Institut Curie	Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024213767A1 (en)	2023-04-14	2024-10-17	Institut National de la Santé et de la Recherche Médicale	Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
WO2024226969A1 (en)	2023-04-28	2024-10-31	Abbott Point Of Care Inc.	Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2024261302A1 (en)	2023-06-22	2024-12-26	Institut National de la Santé et de la Recherche Médicale	Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
TW202515608A (zh)	2023-06-26	2025-04-16	以色列商坎布根有限公司	Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025003193A1 (en)	2023-06-26	2025-01-02	Institut National de la Santé et de la Recherche Médicale	Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
WO2025006811A1 (en)	2023-06-27	2025-01-02	Lyell Immunopharma, Inc.	Methods for culturing immune cells
WO2025012417A1 (en)	2023-07-13	2025-01-16	Institut National de la Santé et de la Recherche Médicale	Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025038763A1 (en)	2023-08-15	2025-02-20	Bristol-Myers Squibb Company	Ceramic hydroxyapatite chromatography flow through method
WO2025050009A2 (en)	2023-09-01	2025-03-06	Children's Hospital Medical Center	Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
WO2025052098A1 (en)	2023-09-08	2025-03-13	Mina Therapeutics Limited	Tmem173 sarna compositions and methods of use
WO2025061993A1 (en)	2023-09-21	2025-03-27	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025061994A1 (en)	2023-09-21	2025-03-27	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025068393A1 (en)	2023-09-27	2025-04-03	Institut Curie	Methods for the treatment of fibrotic related diseases
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202541837A (zh)	2023-12-08	2025-11-01	日商安斯泰來製藥公司	含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025133175A1 (en)	2023-12-21	2025-06-26	Egle Therapeutics	Immunocytokine for cancer treatment
EP4574165A1 (en)	2023-12-21	2025-06-25	Egle Therapeutics	Immunocytokine for cancer treatment
WO2025145207A1 (en)	2023-12-29	2025-07-03	Bristol-Myers Squibb Company	Combination therapy of kras inhibitor and treg-depleting agent
WO2025151487A2 (en)	2024-01-08	2025-07-17	Regents Of The University Of Michigan	Small-molecule inhibitors of adar1
WO2025158077A1 (en)	2024-01-26	2025-07-31	Institut Curie	Lipid degraders to trigger ferroptosis in cancer
WO2025163468A1 (en)	2024-01-30	2025-08-07	Seagen Inc.	Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2025166550A1 (zh) *	2024-02-06	2025-08-14	香港北恒生物科技有限公司	工程化细胞及其用途
TW202543581A (zh)	2024-02-12	2025-11-16	美商艾伊拉醫療公司	遞送組成物
US12521446B2 (en)	2024-02-27	2026-01-13	Bristol-Myers Squibb Company	Anti-CEACAM5 antibody drug conjugates
WO2025184208A1 (en)	2024-02-27	2025-09-04	Bristol-Myers Squibb Company	Anti-ceacam5 antibodies and uses thereof
US20250282776A1 (en)	2024-03-05	2025-09-11	Bristol-Myers Squibb Company	Bicyclic TLR7 Agonists and Uses Thereof
WO2025188694A1 (en)	2024-03-05	2025-09-12	Bristol-Myers Squibb Company	Tricyclic tlr7 agonists and uses thereof
WO2025191529A1 (en)	2024-03-14	2025-09-18	Biohaven Therapeutics Ltd.	Next generation riluzole prodrugs
WO2025202222A1 (en)	2024-03-25	2025-10-02	Institut National de la Santé et de la Recherche Médicale	Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2025202213A1 (en)	2024-03-26	2025-10-02	Institut National de la Santé et de la Recherche Médicale	Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025202450A1 (en)	2024-03-28	2025-10-02	Institut Curie	Myeloid cells modified by cytokine chimeric receptor and uses thereof
EP4624494A1 (en)	2024-03-29	2025-10-01	Institut Curie	Her2 single domain antibody and uses thereof
WO2025210175A1 (en)	2024-04-04	2025-10-09	Centre National De La Recherche Scientifique	Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
WO2025210252A1 (en)	2024-04-05	2025-10-09	Institut Curie	Modulators of fam118b protein for use in therapy
WO2025217094A1 (en)	2024-04-08	2025-10-16	University Of Rochester	Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
WO2025217096A1 (en)	2024-04-08	2025-10-16	University Of Rochester	Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
WO2025219595A1 (en)	2024-04-19	2025-10-23	Biper Therapeutics	Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
WO2025232879A1 (en)	2024-05-10	2025-11-13	Cytocares (Shanghai) Inc.	Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
WO2025245489A1 (en)	2024-05-24	2025-11-27	Bristol-Myers Squibb Company	Treatment of tumors in subjects having fgl-1 positive samples
WO2025248505A1 (en)	2024-05-31	2025-12-04	Wayne State University	Methods for treating endometrial and ovarian hyperproliferative disorders
WO2026006604A1 (en)	2024-06-26	2026-01-02	Lyell Immunopharma, Inc.	Feeder cell replacement
WO2026012976A1 (en)	2024-07-08	2026-01-15	Institut National de la Santé et de la Recherche Médicale	Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
US4681581A (en)	1983-12-05	1987-07-21	Coates Fredrica V	Adjustable size diaper and folding method therefor
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0216846B2 (en)	1985-04-01	1995-04-26	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en)	1986-05-02	1994-12-20	Genentech, Inc.	Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es)	1985-06-26	1992-08-01	Liposome Co Inc	Metodo para acoplamiento de liposomas.
US5776093A (en)	1985-07-05	1998-07-07	Immunomedics, Inc.	Method for imaging and treating organs and tissues
US5101827A (en)	1985-07-05	1992-04-07	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US4735210A (en)	1985-07-05	1988-04-05	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4954617A (en)	1986-07-07	1990-09-04	Trustees Of Dartmouth College	Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4881175A (en)	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
DE3708238A1 (de)	1987-03-16	1988-09-29	Motoren Werke Mannheim Ag	Kraft-waerme-kopplungsanlage
US5013653A (en)	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
DE3853515T3 (de)	1987-05-21	2005-08-25	Micromet Ag	Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US5750172A (en)	1987-06-23	1998-05-12	Pharming B.V.	Transgenic non human mammal milk
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
US5648471A (en)	1987-12-03	1997-07-15	Centocor, Inc.	One vial method for labeling antibodies with Technetium-99m
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
GB8912497D0 (en)	1989-05-31	1989-07-19	Cobbold Stephen P	Monoclonal antibodies
WO1991001754A1 (en)	1989-08-09	1991-02-21	Rhodes Buck A	Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
CA2090473A1 (en)	1990-08-29	1992-03-01	Robert M. Kay	Homologous recombinatin in mammalian cells
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5194594A (en)	1990-09-07	1993-03-16	Techniclone, Inc.	Modified antibodies
WO1992022670A1 (en)	1991-06-12	1992-12-23	Genpharm International, Inc.	Early detection of transgenic embryos
AU2235992A (en)	1991-06-14	1993-01-12	Genpharm International, Inc.	Transgenic immunodeficient non-human animals
DE122007000078I2 (de)	1991-06-27	2011-01-13	Bristol Myers Squibb Co	CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5844095A (en)	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
US5770197A (en)	1991-06-27	1998-06-23	Bristol-Myers Squibb Company	Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE69224906T2 (de)	1991-07-08	1998-10-29	Univ Massachusetts	Thermotropes flüssig-kristallines segment-blockcopolymer
WO1993004169A1 (en)	1991-08-20	1993-03-04	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
US5777085A (en)	1991-12-20	1998-07-07	Protein Design Labs, Inc.	Humanized antibodies reactive with GPIIB/IIIA
EP0592677B1 (en)	1992-02-18	2001-11-07	Otsuka Kagaku Kabushiki Kaisha	Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
EP0652950B1 (en)	1992-07-24	2007-12-19	Amgen Fremont Inc.	Generation of xenogeneic antibodies
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
GB9223377D0 (en)	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5773253A (en)	1993-01-22	1998-06-30	Bristol-Myers Squibb Company	MYPPPY variants of CTL A4 and uses thereof
ES2146648T3 (es)	1993-03-09	2000-08-16	Genzyme Corp	Procedimiento de aislamiento de proteinas de la leche.
CA2161351C (en)	1993-04-26	2010-12-21	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
CA2164288A1 (en)	1993-06-04	1994-12-22	Barbara Ensoli	Method for treating kaposi's sarcoma with antisense oligonucleotides
WO1995001994A1 (en)	1993-07-09	1995-01-19	Synergen, Inc.	Recombinant ctla4 polypeptides and methods for making the same
WO1995003408A1 (en)	1993-07-26	1995-02-02	Dana-Farber Cancer Institute	B7-2: ctl a4/cd 28 counter receptor
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
ES2153895T3 (es)	1994-03-08	2001-03-16	Dana Farber Cancer Inst Inc	Metodos para modular la insensibilidad de celulas t.
US6719972B1 (en) *	1994-06-03	2004-04-13	Repligen Corporation	Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5643763A (en)	1994-11-04	1997-07-01	Genpharm International, Inc.	Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
KR19980701536A (ko)	1995-01-20	1998-05-15	케더린 세레다 글라우브	융합된 세포에서 스크린 효과를 개선시키는 방법
US5703057A (en)	1995-04-07	1997-12-30	Board Of Regents The University Of Texas System	Expression library immunization
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5618912A (en) *	1995-05-04	1997-04-08	Pennzoil Products Company	Tire sealer and inflator compositions
US6410690B1 (en)	1995-06-07	2002-06-25	Medarex, Inc.	Therapeutic compounds comprised of anti-Fc receptor antibodies
US6051227A (en)	1995-07-25	2000-04-18	The Regents Of The University Of California, Office Of Technology Transfer	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en)	1995-07-25	1998-09-22	The Regents Of The University Of California	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en)	1995-07-25	1999-01-05	The Regents Of The University Of California	Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
EP0773288A3 (en)	1995-08-29	1997-07-09	Kirin Brewery	Chimera animal and its method of manufacture
US6025130A (en)	1996-04-04	2000-02-15	Mercator Genetics, Inc.	Hereditary hemochromatosis gene
US5922845A (en)	1996-07-11	1999-07-13	Medarex, Inc.	Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
CA2273194C (en)	1996-12-03	2011-02-01	Abgenix, Inc.	Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP4082740B2 (ja) *	1997-02-28	2008-04-30	キリンファーマ株式会社	内因性遺伝子が破壊されている分化多能性保持細胞
WO1998042752A1 (en) *	1997-03-21	1998-10-01	Brigham And Women's Hospital Inc.	Immunotherapeutic ctla-4 binding peptides
AU7228398A (en)	1997-04-11	1998-11-11	John P. Robarts Research Institute, The	Lck serine phosphorylation assay for t-cell activation and activation-induced cell death
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
CA2205680A1 (en)	1997-05-16	1998-11-16	The University Of Western Ontario	Clip immunomodulatory peptide
US6509057B2 (en)	1998-04-01	2003-01-21	Sumitomo Osaka Cement, Co., Ltd.	Antibacterial, antifungal or antialgal article and process for producing same
CA2241621A1 (en)	1998-06-26	1999-12-26	National Silicates Ltd.	A lubricating method for silicate drilling fluids
TWI255853B (en)	1998-08-21	2006-06-01	Kirin Brewery	Method for modifying chromosomes
DE69938871D1 (de)	1998-12-03	2008-07-17	Univ California	Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen
CA2356215C (en) *	1998-12-23	2015-11-24	Pfizer Inc.	Human monoclonal antibodies to ctla-4
US6682736B1 (en) *	1998-12-23	2004-01-27	Abgenix, Inc.	Human monoclonal antibodies to CTLA-4
ATE354655T1 (de) *	1999-08-24	2007-03-15	Medarex Inc	Humane antikörper gegen ctla-4 und deren verwendungen
US7605238B2 (en)	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
IT1395574B1 (it)	2009-09-14	2012-10-16	Guala Dispensing Spa	Dispositivo di erogazione
US9169311B2 (en)	2013-03-15	2015-10-27	Applied Food Biotechnology, Inc.	Feline bitter taste receptors and methods
KR102264548B1 (ko)	2014-11-21	2021-06-16	삼성전자주식회사	반도체 패키지 및 그 제조 방법

2000
- 2000-08-24 AT AT00959399T patent/ATE354655T1/de active
- 2000-08-24 US US09/644,668 patent/US6984720B1/en not_active Expired - Lifetime
- 2000-08-24 WO PCT/US2000/023356 patent/WO2001014424A2/en not_active Ceased
- 2000-08-24 JP JP2001518753A patent/JP4093757B2/ja not_active Expired - Lifetime
- 2000-08-24 MX MXPA02001911A patent/MXPA02001911A/es active IP Right Grant
- 2000-08-24 EP EP14180954.1A patent/EP2829609A1/en not_active Withdrawn
- 2000-08-24 KR KR1020027002451A patent/KR20020047132A/ko not_active Ceased
- 2000-08-24 DK DK00959399T patent/DK1212422T3/da active
- 2000-08-24 DE DE60033530T patent/DE60033530T2/de not_active Expired - Lifetime
- 2000-08-24 KR KR1020067017019A patent/KR100942863B1/ko not_active Expired - Lifetime
- 2000-08-24 NZ NZ517202A patent/NZ517202A/en not_active IP Right Cessation
- 2000-08-24 EP EP17152917.5A patent/EP3214175A1/en not_active Withdrawn
- 2000-08-24 IL IL14807900A patent/IL148079A0/xx active IP Right Grant
- 2000-08-24 PT PT00959399T patent/PT1212422E/pt unknown
- 2000-08-24 EP EP06077179A patent/EP1792991A1/en not_active Withdrawn
- 2000-08-24 CN CN008120374A patent/CN1371416B/zh not_active Expired - Lifetime
- 2000-08-24 CA CA002381770A patent/CA2381770C/en not_active Expired - Lifetime
- 2000-08-24 ES ES00959399T patent/ES2282133T3/es not_active Expired - Lifetime
- 2000-08-24 EP EP00959399A patent/EP1212422B1/en not_active Expired - Lifetime
- 2000-08-24 CA CA002589418A patent/CA2589418A1/en not_active Abandoned
- 2000-08-24 CN CN201210037538.0A patent/CN102766210B/zh not_active Expired - Lifetime
- 2000-08-24 AU AU70732/00A patent/AU784012B2/en not_active Expired
- 2000-08-24 KR KR1020097003898A patent/KR100996759B1/ko not_active Expired - Lifetime
2002
- 2002-02-10 IL IL148079A patent/IL148079A/en active Protection Beyond IP Right Term
- 2002-02-12 ZA ZA200201190A patent/ZA200201190B/en unknown
2006
- 2006-02-06 JP JP2006029057A patent/JP2006151993A/ja not_active Withdrawn
- 2006-04-11 AU AU2006201520A patent/AU2006201520B9/en not_active Expired
2007
- 2007-04-19 CY CY20071100636T patent/CY1107628T1/el unknown
2008
- 2008-02-20 IL IL189629A patent/IL189629A0/en unknown
2009
- 2009-04-30 JP JP2009111655A patent/JP5599158B2/ja not_active Expired - Lifetime
- 2009-06-18 AU AU2009202447A patent/AU2009202447B2/en not_active Expired
2011
- 2011-12-29 JP JP2011290230A patent/JP2012100674A/ja active Pending
2012
- 2012-01-05 DE DE201212000001 patent/DE122012000001I1/de active Pending
- 2012-01-09 BE BE2012C001C patent/BE2012C001I2/fr unknown
- 2012-01-09 LU LU91928C patent/LU91928I2/fr unknown
- 2012-01-10 FR FR12C0004C patent/FR12C0004I2/fr active Active
- 2012-01-10 CY CY2012002C patent/CY2012002I2/el unknown

Also Published As

Publication number	Publication date
DE60033530D1 (de)	2007-04-05
JP2009213478A (ja)	2009-09-24
FR12C0004I2 (fr)	2013-01-11
IL148079A0 (en)	2002-09-12
EP1212422A2 (en)	2002-06-12
CN102766210A (zh)	2012-11-07
IL148079A (en)	2008-04-13
IL189629A0 (en)	2008-06-05
DE60033530T2 (de)	2007-10-31
AU2006201520A1 (en)	2006-05-11
EP1212422B1 (en)	2007-02-21
DK1212422T3 (da)	2007-07-02
JP2006151993A (ja)	2006-06-15
LU91928I2 (fr)	2012-03-09
CN102766210B (zh)	2015-07-08
KR20020047132A (ko)	2002-06-21
JP5599158B2 (ja)	2014-10-01
AU784012B2 (en)	2006-01-12
KR20060100950A (ko)	2006-09-21
NZ517202A (en)	2004-05-28
PT1212422E (pt)	2007-04-30
CY1107628T1 (el)	2013-04-18
AU2009202447B2 (en)	2011-11-24
EP1792991A1 (en)	2007-06-06
CN1371416B (zh)	2012-10-10
CY2012002I1 (el)	2016-12-14
KR100996759B1 (ko)	2010-11-25
EP3214175A1 (en)	2017-09-06
JP4093757B2 (ja)	2008-06-04
US6984720B1 (en)	2006-01-10
ZA200201190B (en)	2003-05-28
ES2282133T3 (es)	2007-10-16
AU7073200A (en)	2001-03-19
DE122012000001I1 (de)	2012-03-15
FR12C0004I1 (es)	2012-02-24
KR20090036598A (ko)	2009-04-14
CY2012002I2 (el)	2020-05-29
CA2589418A1 (en)	2001-03-01
AU2009202447A1 (en)	2009-07-09
CA2381770C (en)	2007-08-07
AU2006201520B2 (en)	2009-03-19
WO2001014424A2 (en)	2001-03-01
CN1371416A (zh)	2002-09-25
JP2004512005A (ja)	2004-04-22
EP2829609A1 (en)	2015-01-28
BE2012C001I2 (es)	2019-10-16
KR100942863B1 (ko)	2010-02-17
JP2012100674A (ja)	2012-05-31
AU2006201520B9 (en)	2009-08-27
CA2381770A1 (en)	2001-03-01
WO2001014424A3 (en)	2001-09-20
ATE354655T1 (de)	2007-03-15
HK1048831A1 (en)	2003-04-17

Publication	Publication Date	Title
MXPA02001911A (es)	2003-07-21	Anticuerpos ctla-4 humanos y sus usos.
NL300433I1 (en)	2010-03-01	Methods and compositions for the treatment of glomerulonephritis
PT1132403E (pt)	2006-07-31	Peptidos inibidores de tgf g beta1
MXPA02011656A (es)	2004-07-30	Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
MY136095A (en)	2008-08-29	Use of human anti-ctla-4 antibodies for treatment of cancer
IL130931A0 (en)	2001-01-28	Small molecules useful in the treatment of inflammatory disease
MY155218A (en)	2015-09-30	Small molecules useful in the treatment of inflammatory disease
EP1087013A3 (en)	2001-11-28	Immunoglobulins devoid of light chains
IL125124A0 (en)	1999-01-26	Dimeric forms of the protein fapalpha and uses thereof
ZA993364B (en)	2000-12-01	Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
IL142900A0 (en)	2002-04-21	Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
ZA965565B (en)	1997-02-26	Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
ZA200003768B (en)	2002-03-27	Methods and compositions for treating diseases and conditions of the eye.
MXPA03003741A (es)	2003-07-28	Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
FI974640L (fi)	1997-12-30	Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
PL340459A1 (en)	2001-02-12	Agonists of 5ht1f
PT929299E (pt)	2004-02-27	1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b\| benzofuranos substituidos
AU1278600A (en)	2000-06-13	Novel therapeutic application of nicergoline
IL143279A0 (en)	2002-04-21	Novel therapeutic application of low molecular weight heparin
AU7478098A (en)	1998-12-08	Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
AU1278700A (en)	2000-06-13	Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
ZA989313B (en)	2000-04-13	Novel compounds for treating diseases associated with the biological effect of endothelin.
BG101909A (en)	1998-05-29	Pesticides
SI0874843T1 (en)	2002-12-31	Substituted 4-(1h-benzimidazol-2-yl) 1,4)diazepanes useful for the treatment of allergic diseases
PE61999A1 (es)	1999-06-19	Compuestos de tetrahidropiridina

Legal Events

Date	Code	Title
2007-10-03	FG	Grant or registration
2011-07-13	GD	Licence granted
2013-08-09	GB	Transfer or rights